29 T H ANNUAL

SYMPOSIUM OF THE

INTERNATIONAL CANNABINOID

RESEARCH SOCIETY

BETHESDA

M A R Y L A N D , U S A

JUNE 29 – JULY 4, 2019

29 TH A N N U A L

SYMPOSIUM OF THE

INTERNATIONAL CANNABINOID RESEARCH

SOCIETY

BETHESDA

J U N E 2 9 – J U L Y 4 , 2 0 1 9

Symposium Programming by Cortical Systematics LLC

Copyright © 2019

International Cannabinoid Research Society Research Triangle Park, NC

USA

ISBN: 978-604-0-00050-7

These abstracts may be cited in the scientific literature as follows:

Author(s), Abstract Title (2019) 29th Annual Symposium on the Cannabinoids, International Cannabinoid Research Society, Research Triangle Park, NC, USA, Page #. Funding for this conference was made possible in part by grant 2R13DA016280 from the National Institute on Drug Abuse. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

ICRS Sponsors

Government Sponsors

N at io n a l In s t it u t e o n D ru g A b u s e

Non-Profit Organization Sponsors

K a n g T s o u M e m o r ia l F u n d

M o n i q u e C . a n d G e o r g e L . B r a u d e M e m o r i a l F o u n d a t i o n

2019 ICRS Symposium on the Cannabinoids

C o n f e r e n c e C o o r d i n a t o r s

S t e v e A l e x a n d e r , P h . D . H e a t h e r B r a d s h a w , P h D .

M e l a n i e K e l l y , P h . D . P a l P a c h e r , M . D . , P h . D . J a s o n S c h e c h t e r , P h . D .

S a r a W h y n o t

P r o g r a m m e C o m m i t t e e

M a r y A b o o d , P h . D . T a m a s B i r o , M . D . , P h . D .

H e a t h e r B r a d s h a w , P h . D . R e s a t C i n a r , P h . D . D a v i d F i n n , P h . D .

J ü r g G e r t s c h , P h . D . G r z e g o r z G o d l e w s k y , P h . D .

U w e G r e t h e r , P h . D . M a t t H i l l , P h . D .

C e c i l i a H i l l a r d , P h . D . A n d r e a H o h m a n n , P h . D .

T o n y J o u r d a n , P h . D . G e o r g e K u n o s , M . D . , P h . D .

A r o n L i c h t m a n , P h . D . A l e s s i a L i g r e s t i , P h . D . D a v i d L o v i n g e r , P h . D .

K e n M a c k i e , M . D . M a u r o M a c c a r r o n e , P h . D .

J o h n M c P a r t l a n d , D . O . P a l P a c h e r , M . D . , P h . D .

S a c h i n P a t e l M . D . , P h . D . J u l i a n R o m e r o , P h . D .

E t h a n R u s s o , M . D . A n n a - M a r i a S z c z e s n i a k , P h . D .

K a t a r z y n a S t a r o w i c z , P h . D . S a b i n e S t e f f e n s , P h . D .

Y o s s i T a m , D . M . D . , P h . D . M a r i o v a n d e r S t e l t , P h . D .

J e n n y W i l k e r s o n , P h . D .

L i f e t i m e A c h i e v e m e n t A w a r d C o m m i t t e e

M a r y A b o o d , P h . D . R e b e c c a C r a f t , P h . D . M e l a n i e K e l l y , P h . D .

A r o n L i c h t m a n , P h . D .

W i l l i a m D e v a n e Y o u n g I n v e s t i g a t o r A w a r d C o m m i t t e e

A l l y n H o w l e t t , P h . D . C e c i l i a H i l l a r d , P h . D .

L u m í r H a n u š , P h . D . , D . S c . , D r . h . c . m u l t .

S t u d e n t P r i z e s C o m m i t t e e C h a i r

S t e v e A l e x a n d e r , P h . D .

M e c h o u l a m A w a r d C o m m i t t e e

M a r y A b o o d , P h . D . F r a n c i s B a r t h , P h . D .

B e n j a m i n C r a v a t t , P h . D . V i n c e n z o D i M a r z o , P h . D .

C e c i l i a H i l l a r d , P h . D . A l l y n H o w l e t t , P h . D . J o h n H u f f m a n , P h . D .

G e o r g e K u n o s , M . D . , P h . D . G e r a r d L e F u r , P h . D .

A r o n L i c h t m a n , P h . D . B e a t L u t z , P h . D .

K e n M a c k i e , M . D . M a u r o M a c c a r r o n e , P h . D .

A l e x M a k r i y a n n i s , P h . D . R o g e r P e r t w e e , M . A . , D . P h i l , D . S c . , H o n F B P h S

D a n i e l e P i o m e l l i , P h . D . P a t t i R e g g i o , P h . D .

M u r i e l l e R i n a l d i - C a r m o n a , P h . D . A N D R E A S Z I M M E R , P H . D .

2 0 1 9 I C R S B o a r d o f D i r e c t o r s

Executive Director Mel ani e Ke ll y , P h . D .

Pres ident P a l Pac her , M .D . , Ph . D .

Pres ident-Elect Dave F in n , Ph . D .

Past Pres ident H eather Bradsh aw, P h .D .

Secretary Reb e cca Cra ft , Ph .D .

Treasurer St e ve Kin s ey , Ph .D .

International Secretary R oge r Per tw ee , M .A . , D . P hil , D . S c . , Ho nF B P hS

Student Representative Ha le y V ecchi arel l i , B .A . , M .S c .

Grant PI Sa ch in Patel , M . D . , P h .D .

Managing Director Ja s o n Sc hecht er , Ph .D .

Registration: June 29th, 2019 (16.00 – 18.00)

MARRIOTT NORTH CONFERENCE CENTER BETHESDA, MD USA

Welcome Reception: 18.30 – 20.00

Day 1 Sunday, June 30th

7.30 Breakfast

8.30 Welcome and Opening Remarks

Oral Session 1. Cannabis Compounds, Genetics, chemovars and Extraction Methods

CHAIRS: JANA HAJSLOVA AND JOHN MCPARTLAND

8.45 John M. McPartland* and Geoffrey W. Guy

RENAMING DINOSAURS: EXHUMING THE ANCESTORS OF “SATIVA” AND “INDICA”

1

9.00 Carrie Cuttler*,

Alexander Spradlin and Rebecca Craft

SHORT- AND LONG-TERM ACUTE EFFECTS OF CANNABIS ON

HEADACHE AND MIGRAINE: A NATURALISTIC STUDY OF MEDICAL CANNABIS USERS

2

9.15

Lipin Ji, Yingpeng Liu, Fei Tong, Marsha Eno, Shalley Kudalkar, Alex

Straiker, Ai-ling Li, Othman Benchama, Chandrashekhar

Honrao, Anisha Korde, Amey Dhopeshwarkar, Paula Morales, Shu Xu, Michaela

Dvorakova, Dow Hurst, Simiao Wu, JodiAnne T. Wood, Nikolai Zvonok,

Patricia Reggio, Ken Mackie, Lawrence Marnett,

Andrea G. Hohmann, Alexandros Makriyannis

and Spyros P. Nikas*

CHIRAL ENDOCANNABINOID

LIGANDS 3

9.30

L. Cinnamon Bidwell*, Jarrod Ellingson,

Sophie YorkWilliams, Hollis Karoly, Leah N.

Hitchcock, Cristina Sempio, Jost Klawitter,

Brian Tracy, Angela D. Bryan

and Kent E. Hutchison

ACUTE SELF-ADMINISTRATION OF LEGAL MARKET FLOWER AND

CONCENTRATED CANNABIS: CANNABINOID BLOOD LEVELS,

SUBJECTIVE INTOXICATION, AND NEUROBEHAVIORAL OUTCOMES

4

9.45

Jana Hajslova*, Marie Fenclova, Frantisek Benes, Ethan Russo

and Pavel Kubu

ASSESSING TRENDS OF CBD OILS QUALITY AT THE EU MARKET

5

10.00 Coffee Break

Oral Session 2. Cannabidiol

CHAIRS: MICHELLE GLASS AND SAOIRSE O’SULLIVAN

10.30

Salahaden R. Sultan, Timothy J. England

and Saoirse E. O`Sullivan*

ACUTE AND CHRONIC EFFECTS OF CANNABIDIOL ON HAEMODYNAMICS IN

HEALTHY MALES

6

10.45

Staci A. Gruber*, Ashley M. Lambros, Rosemary T. Smith,

M. Kathryn Dahlgren, Kelly A. Sagar, David P. Olson

and Scott E. Lukas

HIGH ANXIETY? EXAMINING THE IMPACT OF FOUR WEEKS OF

TREATMENT WITH A NOVEL HIGH CANNABIDIOL PRODUCT

7

11.00

Tory Spindle*, Edward Cone, John Mitchell,

George Bigelow, Ron Flegel

and Ryan Vandrey

ACUTE PHARMACOKINETICS AND PHARMACODYNAMICS OF ORAL AND VAPORIZED CANNABIDIOL

IN HEALTHY ADULTS

8

11.15 Ewa Galaj*, Guo-Hua Bi

and Zheng-Xiong Xi

CANNABIDIOL ATTENUATES COCAINE REWARD BY CB2, 5-HT1A

AND TRPV1 RECEPTOR MECHANISMS IN RATS

9

11.30 - 12.30

Plenary Speaker

US CANNABIS POLICY: IMPLICATIONS FOR PUBLIC HEALTH

Susan R. B. Weiss, Ph.D.

Director Division of Extramural Research

National Institute on Drug Abuse, Bethesda, MD, USA

12.30 Lunch

12.30

NIDA Student Training Session

OVERVIEW OF NIH/NIDA RESEARCH TRAINING AND GRANT OPPORTUNITIES IN CANNABINOID RESEARCH

BETH BABECKI, WOODY LIN AND RAO RAPAKA

13.30 - 14.30

ICRS Lifetime Achievement Award

CANNABINOID PHARMACOLOGY: MY FIRST HALF CENTURY

Roger Pertwee, M.A., D.Phil, D.Sc., HonFBPhS

Institute of Medical Sciences University of Aberdeen, Scotland

Oral Session 3. CB1 Pharmacology

CHAIRS: RESAT CINAR AND YOSSI TAM

14.30

Thuy Nguyen, Ann M. Decker, Thomas F. Gamage, Jun-Xu Li,

Jenny L. Wiley, Brian F. Thomas, Terry P. Kenakin

and Yanan Zhang*

ALLOSTERIC MODULATORS OF THE CANNABINOID CB1 RECEPTOR: DIARYL UREAS

10

14.45 Allyn C Howlett*, William T. Booth

and W. Todd Lowther

STRUCTURAL ANALYSIS OF THE CB1 CANNABINOID RECEPTOR

INTERACTING PROTEIN 1A (CRIP1A)

11

15.00

Adi Drori*, Asaad Gamal, Shahar Azar, Liad Hinden, Rivka

Hadar, Daniel Wesley, Alina Nemirovski,

Maayan Salton, Boaz Tirosh and Joseph Tam

CANNABINOID-1 RECEPTOR REGULATES SOLUBLE LEPTIN RECEPTOR LEVELS VIA C/EBP

HOMOLOGOUS PROTEIN (CHOP), CONTRIBUTING TO OBESITY-

RELATED HEPATIC LEPTIN RESISTANCE

12

15.15

Resat Cinar*, Nathan J. Coffey, Steven P. Bodine, Joshua K.

Park, Malliga R Iyer, Bernadette R.

Gochuico, William A. Gahl, May Christine V.

Malicdan and George Kunos

MRI-1867, A THIRD GENERATION CB1R ANTAGONIST,

FOR EFFECTIVE THERAPY OF A RARE DISEASE,

HERMANSKY-PUDLAK SYNDROME PULMONARY

FIBROSIS

13

15.30

Michaela Dvorakova, Wesley Corey,

Anaelle Zimmowitch, Alex Straiker*

and Ken Mackie

A CRITICAL EVALUATION OF TERPENOID SIGNALING AT

CANNABINOID CB1 RECEPTORS IN A NEURONAL MODEL

14

15.45

Tania Muller, Julia Leemput, Chloé Buch,

Laurent Demizieux, Patricia Passilly-

Degrace, Resat Cinar, Malliga R Iyer, George Kunos, Bruno Vergès,

Pascal Degrace and Tony Jourdan*

HYBRID INHIBITOR OF PERIPHERAL CANNABINOID-1

RECEPTOR AND INDUCIBLE NITRIC OXIDE SYNTHASE

MITIGATES THE DEVELOPMENT OF DYSLIPIDEMIA

15

16.00 – 18.00 Poster Session 1

Reception

P1

Notes: Presenting Author*

Day 2 Monday, July 1st

7.30 Breakfast

8.30 Opening Remarks

Oral Session 4. CB2 Pharmacology

CHAIRS: UWE GRETHER AND MELANIE KELLY

8.45

U. Grether*, K. Atz, B. Brennecke, E. M.

Carreira, C. Davies, J. Fingerle, T. Gazzi, J. Gertsch, W. Guba, A. Kimbara, C. Korn, M.

Maccarrone, H. Mandhair, R. E. Martin, A. Mason, T. Miljus, M. Nazare, M. Nettekoven, S. Oddi, P. Pacher, A. Pavlovic, A. Pedrina-McCarthy, P. Pfaff, C. Raposo, M. Rogers-Evans, E. Roome, S. Röver, A. Rufer, R.

Sarott, M. Soethoudt, C. Ullmer, M. van der Stelt, D. Sykes, Z. Varga, D.

B. Veprintsev, M. Weise and M. Westphal

FLUORESCENTLY LABELED TYPE-2 CANNABINOID RECEPTOR (CB2R) LIGANDS: FROM INITIAL ATTEMPTS TOWARD A HIGHLY

VERSATILE CHEMICAL TOOLBOX

16

9.00

M. Nazare*, T. Gazzi, B. Brennecke, M. Weise U. Grether, K. Atz, E. M. Carreira, J. Fingerle, J. Gertsch, W. Guba, C.

Korn, M. Maccarrone, H. Mandhair, T. Miljus, S.

Oddi, P. Pacher, A. Pavlovic, P. Pfaff, C. Raposo, A. Rufer, R. Sarott, C. Ullmer, M.

van der Stelt, D. Sykes, Z. Varga, D. B.

Veprintsev and M. Westphal

CB2 RECEPTOR DETECTION BY NEW FLUORESCENTLY

LABELED SYNTHETIC LIGANDS 17

9.15

Zoltan V. Varga*, Katalin Erdelyi, Uwe

Grether, Eszter Trojnar, Catarina Raposo, Jürgen

Fingerle, Christoph Ullmer, Ozge Gunduz-Cinar, Michelle Glass,

Bela Szabo, Miklos Palkovits, Andrew

Holmes, Jürg Gertsch, Julian Romero, Cecilia Hillard and Pal Pacher

CANNABINOID 2 RECEPTOR (CB2) EXPRESSION REVISITED:

DETECTION OF CB2 mRNA WITH NEW SENSITIVE TOOLS

18

9.30

Tomohiro Kimura, Alexei Yeliseev, Mihaela

Mihailescu, Diane L. Lynch, Walter E. Teague

Jr., Kirk G. Hines, Lioudmila Zoubak,

Alan Grossfield, Patricia H. Reggio

and Klaus Gawrisch*

2-AG LOCATION, STRUCTURE AND DYNAMICS IN MEMBRANES

AND ITS INTERACTION WITH CB2 RECEPTORS

19

9.45

Jakub Mlost*, Marta Bryk,

Magdalena Kostrzewa and Katarzyna

Starowicz

CB2 BIASED AGONISTS AND THEIR THERAPEUTIC POTENTIAL

IN OSTEOARTHRITIS 20

10.00 Coffee Break

Oral Session 5. Cannabinoids and Reward

CHAIRS: DAVID FINN AND STEPHANIE LAKE

10.30

Chloe J. Jordan*, Bree Humburg, Yi He, Xiao Han, Guo-hua Bi,

Eliot Gardner, Xiang-qun Xie

and Zheng-Xiong Xi

DISSECTING THE REWARDING VS. AVERSIVE EFFECTS OF CANNABINOIDS: FINDINGS

FROM OPTOGENETIC BRAIN-STIMULATION REWARD

MAINTAINED BY ACTIVATION OF VTA DOPAMINE NEURONS

21

10.45 Joseph F. Cheer* ENDOGENOUS CANNABINOIDS AND REWARD PREDICTION 22

11.00 Matthew L. Eckard* and Steven G. Kinsey

GABAPENTIN ATTENUATES SOMATIC SIGNS OF Δ9-THC

WITHDRAWAL IN MICE 23

11.15

Stephanie Lake*, Thomas Kerr, Jane

Buxton, Zach Walsh, Kanna Hayashi, Evan Wood and M-J Milloy

FREQUENT CANNABIS USE IS ASSOCIATED WITH LOWER

LIKELIHOOD OF FREQUENT ILLICIT OPIOID USE AMONG PEOPLE WHO USE DRUGS WITH CHRONIC PAIN:

A LONGITUDINAL ANALYSIS

24

11.30 - 12.30

Plenary Speaker

THE NEUROBIOLOGY OF DRUG ADDICTION: FROM DRUG REWARD TO HYPERKATIFEIA

TO NEGATIVE REINFORCEMENT

George Koob, Ph.D.

Director National Institute on Alcohol Abuse and Alcoholism

12.30 Lunch

13.30 - 14.00

ICRS Young Investigator Award

ANANDAMIDE, FAAH, STRESS AND ANXIETY: A TRANSLATIONAL JOURNEY

Matt Hill, Ph.D.

Associate Professor The Hotchkiss Brain Institute

University of Calgary, Alberta, Canada

Oral Session 6. Clinical Studies

CHAIRS: NALIN PAYAKACHAT AND ETHAN RUSSO

14.00 Adi Zuloff-Shani*,

Ephraim Brener and Ascher Shmulewitz

EFFICACY AND SAFETY OF THX-110, A PROPRIETARY

THERAPEUTIC COMBINATION OF Δ9-

TETRAHYDROCANNABINOL AND

PALMITOYLETHANOLAMIDE

25

14.15

Nalin Payakachat*, Ryan Vandrey, William E. Fantegrossi, Lauren Russell and Marcel O. Bonn-Miller

DOES CANNABIS HELP IMPROVE INSOMNIA

AMONG PATIENTS WITH POSTTRAUMATIC STRESS

DISORDER?

26

14.30 Carrie Cuttler*, Emily LaFrance and Aria Petrucci

ACUTE EFFECTS OF HIGH POTENCY CANNABIS ON

EVERYDAY LIFE MEMORY 27

14.45

Bitya Raphael*, Natalya Kogan, Malka Attar-Namdar, Mukesh Chourasia, Maria G. Cascio, Avital Shurki, Joseph Tam,

Moshe Neuman, Joseph Foldes, Roger G. Pertwee,

Andreas Zimmer, Itai Bab and Yankel Gabet

HISTONE H4 ENCODES AN ENDOGENOUS PEPTIDE THAT SIGNALS VIA THE

CB2 CANNABINOID RECEPTOR

28

15.00

Mark A. Ware*, Antonio Vigano, Pierre Beaulieu, Andrée Néron, Yola Moride, Michelle Canac-

Marquis, Maja Kalaba, Marc O. Martel, Jordi Perez, Julie

Desroches and William Barakett

THE QUEBEC CANNABIS REGISTRY, A DATABASE

ON THE USE OF CANNABIS FOR MEDICAL

PURPOSES: FINAL RESULTS

29

15.15

Marcel O. Bonn-Miller*, Megan Brunstetter ,

Alexandra Simonian, Hal Wortzel

and Ryan Vandrey

A CONTROLLED PROSPECTIVE

OBSERVATIONAL STUDY OF THE LONGITUDINAL

ASSOCIATIONS BETWEEN CANNABIS USE AND PTSD

SYMPTOMATOLOGY

30

15.30

Dylan Zylla*, Justin Eklund, Grace Gilmore, Alissa

Gavenda, Gabriella VazquezBenitez, Pamala Pawloski, Tom Arneson,

Angela Birnbaum, Stephen Dahmer, Matthew Tracy

and Arkadiusz Dudek

A RANDOMIZED TRIAL OF MEDICAL CANNABIS

IN PATIENTS WITH ADVANCED CANCERS

TO ASSESS IMPACT ON OPIOID USE

AND CANCER-RELATED SYMPTOMS: A PILOT AND

FEASIBILITY STUDY

31

15.45

Joshua Rein*, Lindsay Texter, Mark Wurfel, Edward Siew, Amit Garg, Thida Tan, Paul Kimmel, James Kaufman,

Vernon Chinchilli and Steven Coca

MARIJUANA USE AND KIDNEY OUTCOMES IN

THE ASSESS-AKI COHORT 32

16.00 – 18.00 Poster Session 2

Reception

P2

18.00 Business Meeting

Notes: Presenting Author*

Day 3 Tuesday, July 2nd

7.30 Breakfast

8.30 Opening Remarks

Oral Session 7. Development, Reproductive Function, Smell and Cancer

CHAIRS: ANNA KALINOVSKY AND JULIAN ROMERO

8.45

Kylie Black, Shawyon Baygani, Ricardo Martinez,

Tristen Mier, Alexandria Bell, Ken Mackie

and Anna Kalinovsky*

CANNABINOID SIGNALING REGULATES

CEREBELLAR DEVELOPMENT

33

9.00 Shahnaza Hamidullah*,

Claudia D. Lutelmowskij and Jibran Y. Khokhar

BEHAVIOURAL AND COGNITIVE

EFFECTS OF ADOLESCENT

CANNABIS AND ALCOHOL CO-USE IN

ADULTHOOD

34

9.15 Xiaofei Sun*, Yingju Li,

Fenghua Bian and Sudhansu K. Dey

MICE MISSING CNR1 AND CNR2 SHOW IMPLANTATION

DEFECTS

35

9.30

Ali Mokhtar Mahmoud*, Viviana Marolda, Magdalena

Kostrzewa, Vincenzo Di Marzo, Roberto Ronca

and Alessia Ligresti

NON-PSYCHOTROPIC CANNABINOIDS

SUPPRESS TUMOR GROWTH BY ACTING

ON METABOLIC REPROGRAMMING AND ONCOGENIC PATHWAYS

IN HORMONE REFRACTORY

PROSTATE CANCER

36

9.45 Huizhi Du, Maya Ploss,

Alex Straiker and Thomas Heinbockel*

CANNABINOID RECEPTOR-MEDIATED

MODULATION OF INTERNEURONS IN THE

MAIN OLFACTORY BULB

37

10.00 Coffee Break

10.30 In Memoriam

Oral Session 8. Pain, Stress, Sleep and Psychiatric Disorders

CHAIRS: ANDREA HOHMANN AND DAVE LOVINGER

10.45 David M Lovinger*, Karina P Abrahao and Matthew J Pava

ENDOCANNABINOID ROLES IN SLEEP

STABILITY AND SLEEP DISRUPTION BY

CANNABINOID DRUGS

38

11.00

Madhusudhanan Narasimhan*, Henry Blanton, Jennifer

Brelsfoard, Diana E. Sepulveda, Angela N. Henderson-Redmond,

Daniel J. Morgan and Josée Guindon

CP55,940 ANTINOCICEPTIVE

EFFECT, DEVELOPMENT OF TOLERANCE AND ACTIVATION OF JNK SIGNALING IN THE

CISPLATIN-INDUCED NEUROPATHIC PAIN

MODEL

39

11.15 Douglas E. Brenneman*,

William A. Kinney and Sara Jane Ward

MOLECULAR AND PHARMACLOGICAL EVIDENCE FOR THE SODIUM-CALCIUM

EXCHANGER-1 (mNCX-1) AS A MEDIATOR OF

CBD- AND KLS-13019-APPLIED PROTECTION

AGAINST PACLITAXEL-INDUCED TOXICITY IN

DORSAL ROOT GANGLION CULTURES

40

11.30

Catharine A. Mielnik*, Chun Kit Li, Iain R. Greig, Mostafa H. Abdelrahman,

Laurent A. Trembleau, WM Burnham, Ali Salahpour,

Amy J. Ramsey and Ruth A. Ross

NOVEL NEGATIVE ALLOSTERIC

MODULATOR (NAM) OF CANNABINOID RECEPTOR 1 (CB1)

AMELIORATES SYMPTOMS DUE TO DOPAMINE

DYSREGULATION IN PSYCHIATRIC

DISORDERS

41

11.45

Giulia Donvito*, Ryan Mischel,

Virginia McLane, Daisuke Ogasawara, Hamid Akbarali,

Ku-Lung Hsu, Benjamin F Cravatt

and Aron H Lichtman

THE DIFFERENTIAL ROLE OF

DIACYLGLYCEROL LIPASES IN REVERSING

MECHANICAL SENSITIVITY IN A MOUSE MODEL OF CHEMOTHERAPY-

INDUCED PERIPHERAL NEUROPATHY (CIPN)

42

12.00 – 13.00

Kang Tsou Memorial Lecture

VEGAS AND ULTRA-LSD: NEW CHEMICAL AND SYNTHETIC BIOLOGICAL TECHNOLOGIES

Bryan Roth, M.D., Ph.D.

Director, NIMH Psychoactive Drug Screening Program Distinguished Professor, Department Of Pharmacology

UNC Chapel Hill , NC

13.00 Lunch

13.00 Industry Breakouts

14.00 – 16.00

NIDA Networking Session

CANNABINOID RESEARCH FINDINGS AND FUTURE RESEARCH DIRECTIONS

Chair: Steven Gust, Director, International Program

Division of Neuroscience and Behavior

BASIC RESEARCH OPPORTUNITIES AND PRIORITIES RELATED TO THE CANNABINOIDS

Rita J. Valentino, Division Director

BASIC RESEARCH ON CANNABINOIDS IN DNBR

Roger Sorensen, Chief, Integrative Neuroscience Branch

Division of Therapeutics and Medical Consequences

DEVELOPING CANNABIS-BASED MEDICATIONS, HOW CAN NIDA’S

DIVISION OF THERAPEUTICS AND MEDICAL CONSEQUENCES HELP?

Robert Walsh, Chief, Regulatory Affairs Branch

SUPPORTING CANNABIS RESEARCH IN NIDA’S DIVISION OF THERAPEUTICS AND MEDICAL CONSEQUENCES

Aidan Hampson, Clinical Research Grants Branch

Division of Epidemiology, Services and Prevention Research

NIDA’S CANNABIS POLICY RESEARCH PORTFOLIO: CURRENT AND FUTURE DIRECTIONS

Marsha F. Lopez, Chief, Epidemiology Research Branch

NIDA’S RESEARCH INTERESTS IN THE PREVENTION OF CANNABIS MISUSE

Amy Goldstein, Chief, Prevention Research Branch

NIDA Intramural Research Program

CANNABIS-BASED MEDICATION DEVELOPMENT FOR THE TREATMENT OF SUBSTANCE USE DISORDERS

Zheng-Xiong Xi, Chief, Addiction Biology Unit

COCAINE-INDUCED ENDOCANNABINOID RELEASE MEDIATED BY EXTRACELLULAR VESICLES IN THE VENTRAL TEGMENTAL AREA

Carl Lupica, Chief, Electrophysiology Research Section

Day 4 Wednesday, July 3rd

7.30 Breakfast

8.30 Opening Remarks

Oral Session 9. Immune Function, Neurodegenerative and Cardiovascular Disorders

CHAIRS: IRENE BENITO-CUESTA AND SABINE STEFFENS

8.45

Ines Reynoso-Moreno*, Silvia Tiezt,

Britta Engelhardt, Jürg Gertsch

and Andrea Chicca

NEW STRATEGIES TARGETING THE ENDOCANNABINOID SYSTEM

TO ATTENUATE DISEASE PROGRESSION IN A MOUSE

MODEL OF MULTIPLE SCLEROSIS

43

9.00

Douglas J. Hermes*, Changqing Xu, Rick B. Meeker, Micah J.

Niphakis, Benjamin F. Cravatt, Ken Mackie, Aron H. Lichtman,

Bogna M. Ignatowska-Jankowska

and Sylvia Fitting

GPR18 MEDIATES MICROGLIAL NEUROTOXICITY INDUCED BY HIV-1 TAT PROTEIN IN VITRO

44

9.15

Kevin S. Murnane*, Lindsey Phillips-

Lindsey, Cedrick M. Daphney,

Aboagyewaah Oppong-Damoah,

Richard D. Khusial, Ayman Akil

and Peter N. Uchakin

β-CARYOPHYLLENE IMPROVES MEMORY FUNCTION

AND DECREASES KEY INFLAMMATORY CYTOKINES

IN AGED MICE

45

9.30

Irene Benito-Cuesta*, Samuel Ruiz de Martín

Esteban, Ana M. Martínez Relimpio, M.

Asunción Barreda-Manso, Rosa M. Tolón, Cecilia J.

Hillard, Julián Romero and M. Teresa Grande

THE ROLE OF MICROGLIAL CB2 RECEPTORS IN BETA AMYLOID PHAGOCYTOSIS: IN VITRO AND

IN VIVO STUDIES

46

9.45

Janos Paloczi*, Csaba Matyas, Zoltan V.

Varga, Resat Cinar, György Hasko,

Thomas H. Schindler, George Kunos and Pal Pacher

ALCOHOL BINGE-INDUCED CARDIOVASCULAR

DYSFUNCTION INVOLVES ENDOCANNABINOID-CB1-R

SIGNALING

47

10.00 Coffee Break

Oral Session 10. Endogenous Signaling Systems

CHAIRS: LINDA PARKER AND MARIO VAN DER STELT

10.30 Ephraim Brener*,

Adi Zuloff-Shani and Ascher Shmulewitz

PALMITOYLETHANOLAMIDE MODULATES CB1 AFFINITY

TO THC 48

10.45

Sergiy Tyukhtenko*, Xiaoyu Ma, Kiran

Vemuri, Spyros Nikas, Michael Malamas

and Alexandros Makriyannis

MONOACYLGLYCEROL LIPASE INHIBITION: BIOPHYSICAL AND

MECHANISTIC INSIGHTS 49

11.00 Emma Leishman*, Ken Mackie and

Heather B Bradshaw

ELEVATED LEVELS OF ARACHIDONIC ACID-DERIVED

LIPIDS, INCLUDING PROSTAGLANDINS AND

ENDOCANNABINOIDS, ARE PRESENT THROUGHOUT ABHD12

KO BRAINS: NOVEL INSIGHTS INTO THE NEURODEGENERATIVE

PHENOTYPE

50

11.15

Josephine Watson, Lauren Carnevale, William Arnold, Austin Weigle and Aditi Das*

METABOLISM OF ENDOCANNABINOIDS AND PHYTOCANNABINOIDS BY

CYTOCHROME P450 TO PRODUCE NOVEL BIOACTIVE METABOLITES

51

11.30

Caroline Turcotte, Anne-Sophie Archambault,

Élizabeth Dumais, Cyril Martin, Marie-

Renée Blanchet, Elyse Bissonnette,

Alain Veilleux, Michel Laviolette, Vincenzo Di Marzo

and Nicolas Flamand*

ENDOCANNABINOID HYDROLYSIS INHIBITION

UNRAVELS THAT UNSATURATED FATTY ACIDS INDUCE A ROBUST

SYNTHESIS OF ENDOCANNABINOID-GLYCEROLS

IN HUMAN MYELOID LEUKOCYTES

52

11.45

Linda A. Parker*, Gavin N. Petrie, Kiri

L.Wills, Fabiana Piscitelli, Reem

Smoum , Cheryl L. Limebeer, Erin M. Rock, Samantha Ayoub, Ashlyn

Humphrey, Alexia Gene, Madeleine

Sheppard-Perkins, Marieka DeVuono, Aron H. Lichtman, Vincenzo Di Marzo

and Raphael Mechoulam

OLEOYL GLYCINE INTERFERES WITH ACUTE NALOXONE-PRECIPITATED MORPHINE WITHDRAWAL, BUT NOT

MORPHINE REWARD

53

12.00 Lunch

12.30 Industry Breakouts

Oral Session 11. Wound Healing, Microbiota and Obesity

CHAIRS: ADI DRORI AND MITZI NAGARKATTI

13.30

Natalia Murataeva*, Emma Leishman, Heather Bradshaw and Alex Straiker

A CENTRAL ROLE FOR 2-OLEOYLGLYCEROL IN

CORNEAL WOUND HEALING 54

13.45

Sam R C Johnson*, James J Burston, Victoria J Tyrrell,

Maceler Aldrovandi, Rossa Inglis, Robert

Andrews, Jenna Cash, Paul Martin,

Christopher P Thomas and Valerie B

O'Donnell

12/15 LIPOXYGENASE ORCHESTRATES CELLULAR

REMODELLING DURING WOUND REPAIR

55

14.00

Tania Muller, Laurent Demizieux, Pablo

Ortega-Deballon, Tony Jourdan, Bruno Vergès and Pascal Degrace*

ACTIVATION OF CANNABINOID-1 RECEPTORS (CB1R) IN ADIPOSE

TISSUE CONTRIBUTES TO METABOLIC RISK BY INHIBITING

FAT MOBILIZATION AND ALTERING INSULIN SENSITIVITY

56

14.15

Kathryn Miranda*, William Becker, Brandon Busbee,

Nicholas Dopkins, Yin Zhong, Prakash S. Nagarkatti and Mitzi

Nagarkatti

ENDOCANNABINOID SIGNALING MEDIATES SUSCEPTIBILITY TO

HIGH FAT DIET-INDUCED INTESTINAL DYSBIOSIS AND

REGULATES METABOLIC HEALTH

57

14.30

Cristoforo Silvestri*, Claudia Manca, Niokhor Dione,

Sebastien Lacroix, Ulrike Taschler

Nicolas Flamand, Frederic Raymond and Vincenzo Di

Marzo

BIDIRECTIONAL INTERACTION BETWEEN THE GUT

MICROBIOME AND THE ENDOCANNABINOIDOME

58

14.45

Amira Mohammed*, Hasan Alghetaa,

Marcus Kaul, Prakash Nagarkatti and Mitzi

Nagarkatti

THC TREATMENT IMPROVED NEUROTOXICITY BY ALTERING

THE MICROBIOTA 59

15.00 – 16.00

President’s Lecture

THE STRUCTURES AND FUNCTIONS OF

THE CANNABINOID RECEPTORS

Alexandros Makriyannis, Ph.D.

George D. Behrakis Chair of Pharmaceutical Biotechnology Director, Center for Drug Discovery (CDD) Northeastern University, Boston, MA, USA

16.00 – 18.00 Poster Session 3 P3

18.30 Reception

19.00

ICRS BANQUET

AND

AWARDS CEREMONY

Departure: Thursday, July 4th

Notes: Presenting Author*

POSTER SESSION P1

Sunday, June 30th: 16:00 - 18:00

Johanna Baas*, Ivo Heitland, Renate de Bock, Minne Prüst

and Iris Schutte

DOES ADMINISTRATION OF CANNABIDIOL ENHANCE EXTINCTION

OF FEAR IN HUMANS? P1-1

Daniel Barrus*, Purvi Patel, Thuy Nguyen, Charlotte Farquhar,

Tim Lefever, Yanan Zhang, Jenny Wiley, Thomas Gamage

and Brian Thomas

PHARMACOLOGICAL CHARACTERIZATION OF THE

SYNTHETIC CANNABINOID EG-018 P1-2

Paula Berman*, Liron Sulimani, Anat Gelfend, Keren Amsalem, Liran Baram, Gil Lewitus, Igal Louria-Hayon and David Meiri

CANNABINOIDOMICS – AN ANALYTICAL TOOL TO

UNDERSTAND THE EFFECT OF MEDICAL CANNABIS TREATMENT

P1-3

Stefan Brand*, Hans-Jürgen Niemeyer, Carsten Röttger

and Matthias Winkler

ENANTIOMERIC EXCESS DETERMINATION OF SYNTHETIC

CANNABINOIDS P1-4

Chris Breivogel*, Anicet Tresor Padjio Tchuisseu

and Nshan Muradyan

CBD BLOCKS THE SEIZURE-INDUCING ACTIVITY OF CP55940 P1-5

John Brunstein*, May Cui, Jerian Reynolds, Kevin She and Ying Ng

LACK OF STANDARDIZATION IN CANNABIS VARIETY NAMES IN BOTH GREY MARKET AND LEGAL SUPPLY CHAINS IN CANADA: EVIDENCE FOR

NECESSITY OF GENETIC VERIFICATION

P1-6

Marta Baranowska–Kuczko*, Hanna Kozłowska, Monika Kloza,

Olga Sadowska and Barbara Malinowska

CHRONIC CANNABIDIOL TREATMENT IMPROVES VASCULAR FUNCTION OF HYPERTENSIVE DOCA-SALT RATS IN VASCULAR BED SPECIFIC MANNER

P1-7

Lukasz Ciesla*

CELLULAR MEMBRANE AFFINITY CHROMATOGRAPHY (CMAC) AS A TOOL

TO IDENTIFY PHARMACOLOGICALLY ACTIVE COMPOUNDS INTERACTING WITH TRANSMEMBRANE PROTEINS

P1-8

Nathan J. Coffey*, Bernadette R. Gochuico, Joshua K. Park,

Tony Jourdan, Kevin J. O’Brien, William A. Gahl, George Kunos

and Resat Cinar

CANNABINOID CB1R RECEPTOR IS OVERACTIVATED IN HERMANSKY-PUDLAK SYNDROME

PULMONARY FIBROSIS

P1-9

John Brunstein, May Cui*, Jerian Reynolds and Ying Ng

APPLICATION OF OXFORD NANOPORE MINION PLATFORM IN CANNABIS GENOMICS AND METAGENOMICS:

FIRST IMPRESSIONS

P1-10

Gregory G. Martin, Friedhelm Schroeder, Cecilia J. Hillard

and Christopher W. Cunningham*

DISCOVERY OF STEROL CARRIER PROTEIN-2 INHIBITORS USING

RATIONAL PROBE DESIGN P1-11

Marieka V. DeVuono*, Alexandra Bath, Erin M. Rock, Cheryl M. Limebeer and Linda A. Parker

NAUSEA PRODUCED BY HIGH DOSE THC: ASSESSMENT OF

PHARMACOLOGICAL TREATMENTS P1-12

Tama Evron*, Hongfeng Deng, Gang Sun, Alison O’Mahony,

Xiao Feng, Mark Tepper, Sergei Atamas and Barbara White

SELECTIVE INHIBITION OF THE CANNABINOID RECEPTOR CB1 FOR

THE TREATMENT OF INFLAMMATION AND FIBROSIS

P1-13

David B. Finlay*, Jamie J. Manning, Christa E. Macdonald,

Mikkel S. Ibsen, Samuel D. Baniste and Michelle Glass

CHARACTERISATION OF AMB-FUBINACA: A BIASED

AGONIST AND TOXIC SYNTHETIC CANNABINOID OF ABUSE

P1-14

Ryan Taché and Constance Finley*

COMPOUNDING OF CANNABIS PRODUCTS WITH SPECIFIC PLANT

DERIVED ESSENTIAL OIL CONSTITUENTS FOR TARGETED

THERAPIES

P1-15

Daniel H. Foil*, Kimberley M. Zorn, Alex M. Clark

and Sean Ekins

APPLYING MACHINE LEARNING TO ENDOCANNABINOID TARGETS

WITH ASSAY CENTRAL P1-16

Thomas F. Gamage*, Charlotte E. Farquhar, Daniel Barrus, Tony

Landavazo, Joseph Wilson, Brian F. Thomas, Bruce E. Blough

and Jenny L. Wiley

STRUCTURE-ACTIVITY RELATIONSHIP STUDIES OF

CB1 PAM 2-PHENYLINDOLE SCAFFOLD P1-17

Grzegorz Godlewski*, Resat Cinar, Nathan J. Coffey, Jie Liu,

Tony Jourdan, Ozge Gunduz Cinar, Bani Mukhopadhyay, Lee

Chedester, Ziyi Liu, Douglas Osei-Hyiaman, Malliga R. Iyer, Joshua K. Park, Roy G. Smith, Hiroshi

Iwakura and George Kunos

PERIPHERAL CB1 RECEPTOR BLOCKADE REDUCES VOLUNTARY

ALCOHOL DRINKING BY INHIBITING THE FORMATION OF BIOLOGICALLY

ACTIVE GHRELIN THROUGH A CB1-DEPENDENT FATTY ACID OXIDATION IN THE STOMACH

AND ITS SIGNALLING VIA GASTRIC VAGAL AFFERENTS IN MICE

P1-18

Adrianne Wilson-Poe, Eric Larsen, Conan Liu and Ari Greis*

VARIABILITY AND PAUCITY OF MEDICALLY RELEVANT CANNABIS PRODUCTS IN STATE REGULATED CANNABIS RETAIL DISPENSARIES

P1-19

Michael Grider* TRANSCRIPTOME-LEVEL ANALYSIS OF CBD-MEDIATED NEUROPROTECTION IN

A SEROTONERGIC CELL LINE P1-20

Tobias Gutowski* and Regina Scherließ

EVALUATION OF THE RESPIRABLE FRACTION OF CANNABIDIOL METERED

DOSE INHALERS P1-21

Antonei B. Csoka, Marcus D. Sojourner

and Thomas Heinbockel*

EPIGENETIC ANALYSIS OF THE EFFECTS OF A SYNTHETIC CANNABINOID P1-22

Dow P. Hurst*, David B. Finlay, Diane L. Lynch, Michelle Glass

and Patricia H Reggio

CB1 MUTATIONS TO TEST THE RELEVANCE OF TARANABANT CONTACT WITH N-TERMINAL RESIDUES F102 AND M103 IN CB1 CRYSTAL STRUCTURE

P1-23

Sri Sujana Immadi*, Zhixing Wu, Rachel Dopart, Mohammad

Mustafa, Giulia Donvitor, Aron H. Lichtman, Debra A. Kendall

and Dai Lu

STRUCTURE-ACTIVITY RELATIONSHIP STUDIES OF POSITIVE ALLOSTERIC

MODULATORS OF THE CANNABINOID CB1 RECEPTOR

P1-24

Israa Isawi*, Paula Morales, Dow Hurst, Nadine Jagerovic

and Patricia Reggio

GPR6: MODEL DEVELOPMENT, DRUG DESIGN AND SYNTHESIS P1-25

Ian R. Jacobs*, Changqing Xu, Douglas J. Hermes, Alexis League,

Callie Xu, Micah J. Niphakis, Benjamin F. Cravatt, Ken Mackie,

Aron H. Lichtman, Bogna M. Ignatowska-Jankowska

and Sylvia Fitting

INHIBITORY CONTROL DEFICITS ASSOCIATED WITH UPREGULATION OF CB1R IN THE HIV-1 TAT TRANSGENIC

MOUSE MODEL OF HAND

P1-26

Kavita M. Jeerage*, Chris L. Suiter, Elijah N. Holland,

Megan E. Harries, Jason A. Widegren

and Tara M. Lovestead

FUNDAMENTAL PARTITIONING RELATIONSHIPS OF COMPOUNDS

INDICATIVE OF CANNABIS PLANTS OR CANNABIS EXPOSURE

P1-27

Bryan W Jenkins*, Tapia Foute Nelong, Samantha D Creighton,

Boyer D Winters, Melissa L Perreault

and Jibran Y Khokhar

LASTING DECREASE OF CORTICOSTRIATAL COHERENCE

IN RATS AFTER ACUTE EXPOSURE TO VAPOURIZED

∆9-TETRAHYDROCANNABINOL

P1-28

Steven G. Kinsey*, Matthew L. Eckard and Kristen R. Trexler

THE CB1 POSITIVE ALLOSTERIC MODULATOR ZCZ011 BLOCKS ∆9-THC WITHDRAWAL IN MICE

P1-29

Yi William Yang, Rupali Vyawahare, Justin Ryk, Albert H.C. Wong, Hance A. Clarke

and Lakshmi P. Kotra*

CHEMICAL COMPOSITION-ACTIVITY ANALYSES OF 59 MEDICAL

CANNABIS SAMPLES: A MEDICINAL CHEMISTRY APPROACH

P1-30

Stefan Kuprowsky*

INTEGRATING CANNABIDIOL WITH MITOCHONDRIAL MODIFIERS

IN THE TREATMENT OF PTSD AND PSYCHOSIS

P1-31

Luciana Leo*, Rufaida Al Zoubi, Pingwei Zhao, Daohai Yu,

Eugen Brailoiu, Patricia H. Reggio and Mary E. Abood

MUTATIONAL ANALYSIS REVEALS BIASED SIGNALING AT THE CB1

CANNABINOID RECEPTOR P1-32

Dai Lu*, Zhixing Wu, Sri Sujana Immadi, Rachel Dopart,

Mohammad Mustafa, Giulia Donvitor, and Aron H. Lichtman,

Kristen R Trexler, Steven G. Kinsey and Debra A. Kendall

DESIGN AND SYNTHESIS OF 3-AMINO-2-PHENYL INDOLE ANALOGS AS NOVEL ACHIRAL LIGANDS FOR ALLOSTERIC MODULATION OF THE CB1 RECEPTOR

P1-33

Ryan Maguire*, Ronan Lee, Saoirse E. O’Sullivan

and Timothy J England

A META-ANALYSIS ON THE EFFECTS OF CANNABIDIOL IN

EXPERIMENTAL STROKE P1-34

Ryan F Maguire*, Timothy J England and Saoirse E O’Sullivan

THE PHARMACOLOGICAL EFFECTS OF SYNTHETIC OR PLANT-DERIVED CANNABIDIOL (CBD) ARE SIMILAR

IN A RANGE OF HUMAN CELL LINES

P1-35

George Amato, Amruta Manke, Robert Wiethe, Vineetha

Vasukuttan, Rodney Snyder, Yun Lan Yueh, Ann Decker, Scott Runyon, Nayaab Khan

and Rangan Maitra*

DEVELOPMENT OF A PERIPHERALLY RESTRICTED CB1 RECEPTOR ANTAGONIST FOR ALCOHOL

INDUCED LIVER DISEASE

P1-36

Soumyajit Majumdar*, Mahmoud A. ElSohly,

Waseem Gul and Brian Murphy

DEVELOPMENT OF AN INTRAOCULAR PRESSURE LOWERING, OPHTHALMIC FORMULATION CONTAINING THE Δ9-TETRAHYDROCANNABINOL (Δ9-THC) PRODRUG, Δ9-THC-VAL-HS (NB1111)

P1-37

Chandrani G. Majumdar*, Suman Chandra, Mohamed M. Radwan,

James C. Church and Mahmoud A. ElSohly

POTENCY OF CANNABIS AND RELATED PRODUCTS IN THE USA

DURING THE PERIOD 2008-2018 P1-38

Barbara Malinowska*, Anna Pędzińska-Betiuk, Marek Toczek,

Michał Biernacki, Magdalena Timoszuk, Anna Jastrząb, Jolanta Weresa and Patryk Remiszewski

INFLUENCE OF CHRONIC CANNABIDIOL ADMINISTRATION ON

CARDIOVASCULAR PARAMETERS, ENDOCANNABINOID LEVELS AND OXIDATIVE STRESS IN

SPONTANEOUSLY HYPERTENSIVE AND NORMOTENSIVE RATS

P1-39

Yehoshua Maor*, Lior Sinai and Lumir Hanus

TOXICOLOGICAL PROFILE OF SELECTED TERPENOIDS PRESENT IN CANNABIS AND IN OTHER PLANTS – FOCUS ON BETA-CARYOPHYLLENE

P1-40

Amna C. Mazeh*, James A. Angus and Christine E. Wright

AN ESTIMATION OF THE CB1 RECEPTOR ANTAGONISM OF CANNABIDIOL ON a1-ADRENOCEPTOR-MEDIATED

CONTRACTIONS OF RAT VASA DEFERENTIA

P1-41

Ana Martín-Sánchez, Guillermo Moreno-Sanz*, Adriana Castro-

Zavala, Carlos Ferreiro-Vera, Xavier Nadal, Olga Valverde

and Verónica Sánchez de Medina

CANNABIDIOL BLOCKS THE HYPO-LOCOMOTIVE EFFECT

OF Δ9-THC THROUGH A GLUTAMATERGIC/DOPAMINERGIC-

DISCRIMINATING MECHANISM

P1-42

Raeghan L. Mueller*, Sophie L. YorkWilliams, L. Cinnamon Bidwell, Timothy Helmuth, Angela D. Bryan

and Kent E. Hutchison

THE PRESENCE OF CBD IN CANNABIS FLOWER MODERATES THE

RELATIONSHIP BETWEEN BLOOD THC CONCENTRATION AND FATTY ACID AMIDE HYDROLASE (FAAH)

GENOTYPES

P1-43

Mohammed Mustafa*, Giulia Donvito, Debra Kendall, Dai Lu

and Aron H. Lichtman

IN VIVO INVESTIGATION OF THE (R)- AND (S)-STEREOISOMERS OF THE CB1 POSITIVE ALLOSTERIC

MODULATOR (PAM) ZCZ011

P1-44

Thuy Nguyen*, Thomas Gamage, Ann Decker, Tiffany L. Langston,

Daniel Barrus, Brian F. Thomas and Yanan Zhang

SYNTHESIS AND PHARMACOLOGICAL EVALUATION OF DIARYLUREA

BASED ALLOSTERIC MODULATORS OF CB1 RECEPTOR

P1-45

Alex Nivorozhkin* and Michael Palfreyman

DRUG DELIVERY AND FORMULATION OF CANNABINOIDS P1-46

Belén Palomares*, Martin Garrido, Claudia Gonzalo, María Gómez Cañas, Javier Fernández-Ruiz, Giovanni Appendino, Gaetano Morello and Eduardo Muñoz

CHARACTERIZATION OF D9-TETRAHYDROCANNABINOLIC

ACID AS A DUAL PPARg/ CB1 LIGAND. IMPLICATIONS IN RHEUMATOID ARTHRITIS

P1-47

Cory Parks*, Byron C. Jones, Bob M. Moore II

and Megan K. Mulligan

IDENTIFICATION OF SEX, STRAIN, AND ENTOURAGE EFFECTS IN THE

BEHAVIORAL AND PHYSIOLOGICAL RESPONSE TO CANNABINOIDS

P1-48

Jimit Girish Raghav*, Kiran Vemuri, Spyros P. Nikas, Joseph Anderson, Shashank Kulkarni,

Torbjörn U. C. Järbe and Alexandros Makriyannis

EVALUATING NOVEL CONTROLLED DEACTIVATION CANNABINOID

AGONISTS WITH REDUCED TOLERANCE AND DEPENDENCE PROFILES

P1-49

Kelly A. Sagar*, M. Kathryn Dahlgren, Rosemary T. Smith,

Ashley M. Lambros, Madeline K. Kuppe, Laura Patriarca

and Staci A. Gruber

MEDICAL CANNABIS: AVENUE TO ALLEVIATION OR PATH TO PROBLEMATIC USE?

P1-50

Savanah L. Saldaña*, Henar Hernandez-Galante, Rachel G. Lange, Todd M.

Stollenwerk, Andrew D. Rosicky, Cecilia J. Hillard

and Christopher W. Cunningham

ALKALOID-BASED CB1 RECEPTOR ALLOSTERIC MODULATORS P1-51

Laura Santos*, Mario Amores, María Ceprián, Laura López-

Gómez, Medardo Hernández, Vitor Samuel Fernandes, María Gómez-

Ruiz, Ana Sofía Ribeiro and María Ruth Pazos

BLADDER DISFUNCTION AS A CONSEQUENCE ON NEONATAL

HYPOXIC-ISCHEMIC BRAIN DAMAGE: PROTECTIVE ROLE OF CBD

P1-52

Todd M. Stollenwerk*, Savanah L. Saldaña, Cecilia J. Hillard

and Christopher W. Cunningham

CWC-1-001 EXHIBITS CB1 RECEPTOR ALLOSTERIC MODULATORY EFFECTS P1-53

Nicole Stone*, Timothy J. England and Saoirse E. O’Sullivan

ANTIINFLAMMATORY AND NEUROPROTECTIVE EFFECTS OF

CANNABIDIOLIC ACID (CBDA) UNDER HYPOXIC CONDITIONS IN VITRO

P1-54

Michael Udoh*, Marina Santiago, Marika Heblinski, Iain McGregor

and Mark Connor

CANNABICHROMENE ACTIVITY AT CB1 AND CB2 RECEPTORS VIA MULTIPLE

SIGNALLING PATHWAYS P1-55

Jenny L. Wilkerson*, Jasmine S. Felix, Aron H. Lichtman and Lance R. McMahon

THE MARIJUANA-DERIVED TERPINE α-TERPINEOL REVERSES MECHANICAL

ALLODYNIA AND THERMAL HYPERALGESIA IN A MOUSE MODEL

OF NEUROPATHIC PAIN

P1-56

Lucie Foster and Karen Wright*

COMPARISON BETWEEN DRAGONFLY CANNABIDIOL VS TOCRIS

CANNABIDIOL IN COLORECTAL CANCER SPHEROIDS

P1-57

Zhixing Wu*, Sri Sujana Immadi, Rachel Dopart, Kristen R. Trexler,

Steven G. Kinsey, Debra A. Kendall and Dai Lu

OPTIMIZED SYNTHESIS OF ZCZ011, RESOLUTION AND CHARACTERIZATION

OF ITS ENANTIOMERS P1-58

Kimberley M. Zorn*, Daniel H. Foil, Alex M. Clark

and Sean Ekins

APPLYING MACHINE LEARNING TO CANNABINOID DRUG DISCOVERY

WITH ASSAY CENTRAL P1-59

Sandeep Kumar*

POTENT ANTI-INFLAMMATORY EFFECTS OF CANNABIDIOL (CBD)

TO MODULATE INDUCED INFLAMMATION ON GINGIVAL

KERATINOCYTES: IN VITRO STUDY

P1-60

Notes: Presenting Author*

POSTER SESSION P2

Monday, July 1st: 16:00 - 18:00

Yousra Adel* and Steve PH Alexander

A COMPARISON OF LIGAND-EVOKED SIGNALLING THROUGH MULTIPLE

PATHWAYS (CAMP, CA2+, ERK) IN CB2 RECEPTOR RECOMBINANT EXPRESSION

P2-1

Lucas Albrechet-Souza*, Kimberly N. Whisler

and Nicholas W. Gilpin

PREDATOR ODOR STRESS ALTERS ENDOCANNABINOID SYSTEM PROTEIN

EXPRESSION IN THE RAT BASOLATERAL AMYGDALA

P2-2

Jason SE Loo, Abigail L Emtage and Steve PH Alexander*

INTERPRETING THE STRUCTURES OF THE CANNABINOID RECEPTORS P2-3

Samantha M. Ayoub*, Cheryl L. Limebeer, Linda A. Parker and Raphael Mechoulam

THE EFFECT OF OLEOYL-GLYCINE ON REINSTATEMENT OF PREVIOUSLY

EXTINGUISHED MORPHINE PLACE PREFERENCE IN RATS

P2-4

Liran Baram*, Ella Peled, Ben Yellin, Paula Berman

and David Meiri

CANNABIS EXTRACTS AS ANTI-TUMOR AGENTS: EVIDENCE

FROM CANCER CELL LINES P2-5

Alexandria Bell*, Ricardo Martinez, Kylie Black,

Jonah Wirt, Ken Mackie and Anna Kalinovsky

LOCALIZATION OF ENDOCANNABINOID SYNTHESIZING ENZYME NAPE-PLD

DURING CEREBELLAR DEVELOPMENT P2-6

Zvi Bentwich*, Timna Naftali, Naama Saban

and Lihi Barlev-Schleider

CUMULATIVE EXPERIENCE FROM CLINICAL TRIALS IN ISRAEL:

REALITIES AND CHALLENGES P2-7

Kylie Black*, Shawyon Baygani, Brynna Webb, Ricardo Martinez, Amanda Essex, Emma Leishman, Heather Bradshaw, Ken Mackie

and Anna Kalinovsky

PERINATAL EXPOSURE TO THC DISRUPTS CEREBELLAR DEVELOPMENT P2-8

Nicole Bowles*, Saurabh Thosar, Maya Herzig, Noal Clemons, Garret Sauber, Alicia Stewart,

Andrew McHill, Jonathan Emens, Cecilia Hillard and Steven Shea

BODY MASS INDEX BUT NOT SLEEP IMPACTS THE

ENDOGENOUS CIRCADIAN RHTYHM OF THE ENDOCANNABINOID

ANADAMIDE IN HUMANS

P2-9

Megan Sanctuary, Cinthia Wilkinson, Ashleigh Jones, Brittany Murphy, Edward

Hoffenberg, Cecilia Hillard, Julian Romero and Colm Collins*

CELL-SPECIFIC CB2R DEFICIENCY ATTENUATES CHRONIC INTESTINAL

INFLAMMATION P2-10

Courtney Collins*, Heather Jackson, Nicolas J. Schlienz, Erin Martin, Ryan Scalsky, Marcel O.

Bonn-Miller, Joel Munson and Ryan Vandrey

THE REALM OF CARING OBSERVATIONAL

RESEARCH REGISTRY: EVALUATING THE HEALTH IMPACTS OF

MEDICINAL CANNABIS USE

P2-11

Luis Colón-Cruz*, Agnes Acevedo-Canabal, Roberto Rodriguez-Morales, Gaurav Varshney, Shawn Burgess,

Guillermo Yudowski and Martine Behra

AN UP-SCALABLE COMBINED GENETIC-BEHAVIORAL APPROACH USING CB2-KO ZEBRAFISH LARVAE

P2-12

Kevin M. Crombie*, Brianna N. Leitzelar, Angelique G. Brellenthin, Cecilia J. Hillard

and Kelli F. Koltyn

LOSS OF STRESS- AND EXERCISE-INDUCED INCREASES IN CIRCULATING

2-ARACHIDONOYLGLYCEROL CONCENTRATIONS IN ADULTS

WITH PTSD

P2-13

Mary Kathryn Dahlgren*, Atilla Gonenc, Kelly A. Sagar, Rosemary T. Smith, Ashley M. Lambros, Madeline K. Kuppe,

Laura Patriarca and Staci A. Gruber

IMPROVED WHITE MATTER INTEGRITY FOLLOWING THREE AND SIX MONTHS OF MEDICAL CANNABIS TREATMENT

P2-14

Andrea Tomko, Hilary Trask and Denis J. Dupré*

EFFECTS OF ATYPICAL CANNABINOIDS ON BREAST CANCER CELLS VIABILITY P2-15

Alice Domenichini, Aleksandra Adamska, Ilaria Casari

and Marco Falasca*

TESTING CANNABINOIDS IN HUMAN PANCREATIC CANCER MODELS IN

COMBINATION WITH CURRENT CHEMOTHERAPY AGENTS

P2-16

Faiha Fareez*, Phillip Olla, Kaitlyn Abeare, Nora McVinnie,

Maurissa Hastings and Laszlo A Erdodi

THE EFFECT OF CANNABIS ON PERFORMANCE DURING

NEUROPSYCHOLOGICAL TESTING P2-17

Caroline Turcotte, Élizabeth Dumais, Anne-Sophie

Archambault, Cyril Martin, Marie-Renée Blanchet, Élyse

Bissonnette, Michel Laviolette, Vincenzo Di Marzo

and Nicolas Flamand*

HUMAN LEUKOCYTES DIFFERENTIALLY EXPRESS

ENDOCANNABINOID-GLYCEROL LIPASES AND HYDROLYZE

2-ARACHIDONOYL-GLYCEROL AND ITS METABOLITES FROM

THE CYCLOOXYGENASE-2 AND 15-LIPOXYGENASE PATHWAYS

P2-18

Tamara Miljuš, Franziska M. Heydenreich, Thais Gazzi*,

Atsushi Kimbara, Mark Rogers-Evans, Matthias Nettekoven,

Arne Rufer, Christoph Ullmer, Wolfgang Guba, Christian Le

Gouill, Jürgen Fingerle, Marc Nazaré, Uwe Grether,

Michel Bouvier and Dmitry B. Veprintsev

CANNABINOID RECEPTORS BIASED SIGNALLING – IN DEPTH PATHWAY

ANALYSIS APPLYING A DIVERSE COMPOUND LIBRARY

P2-19

Rosamond M. Goodson*, Erica N. Golden, Leandro F.

Vendruscolo, George F. Koob and Joel E. Schlosburg

REWARDING PROPERTIES OF HEROIN DURING ACUTE DOSING,

TOLERANCE, SELF-ADMINISTRATION, DEPENDENCE, AND WITHDRAWAL:

IMPACT OF FATTY ACID AMIDE HYDROLASE (FAAH) INACTIVATION

P2-20

Zachary D.W. Dezman, David A. Gorelick*, Laura Buchanan

and Carl A. Soderstrom

CANNABIS USE DISORDER AND LONG-TERM POST-DISCHARGE

SURVIVAL IN TRAUMA INPATIENTS P2-21

Briana Hempel*, Madeline Crissman, Mariam Melkumyan,

Chloe Winston, Jacob Madar and Anthony L. Riley

THE EFFECTS OF CROSS-GENERATIONAL

Δ9-TETRAHYDROCANNABINOL EXPOSURE ON NICOTINE

RESPONSIVITY IN ADULT OFFSPRING

P2-22

Bogna M Ignatowska-Jankowska*, Alexander Kuck and Marylka Yoe Uusisaari

KINEMATIC SIGNATURES OF CANNABINOID SIGNALING IN MICE:

CP55,940 P2-23

Christos Iliopoulos-Tsoutsouvas*, Spyros P. Nikas, Shan Jiang,

Wen Zhang, Simiao Wu, Nikolai Zvonok, Jimit Girish Raghav, Robert B. Laprairie, Joseph B.

Anderson, Laura M. Bohn and Alexandros Makriyannis

NOVEL MONO AND BIFUNCTIONAL CANNABINOIDS RECEPTOR PROBES P2-24

Isis Janilkarn-Urena*, Kristiana Peraza, R. Michael Little, Juanita Jellyman and Nancy E. Buckley

THE ROLE OF THE CANNABINOID RECEPTOR (CB#R) AND SEX DURING A MOUSE CANDIDA ALBICANS INFECTION

P2-25

Attila Keresztes* and John M Streicher

INVESTIGATION OF THE MECHANISM OF CANNABINOID-INDUCED CANCER

CELL SENSITIZATION AND CELL DEATH VIA THE ACTIVATION OF DR4 AND DR5

DEATH RECEPTORS IN THE LN-18 GLIOBLASTOMA CELL LINE

P2-26

Debra Kimless*, Heather Denham and Stephen Goldner

SMART PHONE APPLICATION FOR THE REAL-TIME ACQUISITION OF CLINICAL TRIAL DATA AND REAL-TIME CAPTURE AND RESPONSE OF ADVERSE EFFECTS

AND COMPLIANCE ASSURANCE

P2-27

Rik Kline*, Robert Walsh, Steven Gust, Brian Thomas

and Mahmoud ElSohly

MARIJUANA AND CANNABINOID RESEARCH PRODUCTS AVAILABLE FROM THE NATIONAL INSTITUTE

ON DRUG ABUSE

P2-28

Alexus S. Longo and Linda E. Klumpers*

ANALYSIS OF COVARIATES ASSOCIATED WITH SELF-REPORTED

CANNABIS USE DISORDER SYMPTOMS P2-29

Lakshmi P. Kotra*, Hance A. Clarke and Albert H.C. Wong

MEDICAL CANNABIS, PAIN AND PTSD: PATIENTS-CENTRIC STUDIES IN

TWO TORONTO HOSPITALS P2-30

Yi William Yang, Justin Ryk, Albert H.C. Wong, Hance A.

Clarke and Lakshmi P. Kotra*

MEDICAL CANNABIS DERIVATIVE PRODUCTS:

PRODUCT QUALITY, BIOCHEMISTRY AND CLINICAL RELEVANCE

P2-31

Lakshmi P. Kotra*, Justin Ryk, Yi William Yang, Melissa M.

Lewis-Bakker, Rupali Vyawahare, Ewa Wasilewski,

Hance A. Clarke and Albert H.C. Wong

POST-TRAUMATIC STRESS DISORDER (PTSD) AND MEDICAL CANNABIS: CONNECTING 22 PATIENTS’ DATA

P2-32

Lakshmi P. Kotra*, Yi William Yang, Ewa Wasilewski, Rupali Vyawahare, Melissa M. Lewis-

Bakker and Hance A. Clarke

A PRAGMATIC INVESTIGATION INTO MEDICAL CANNABIS

FOR CHRONIC PAIN P2-33

Albert Dahan, Tine van de Donk, Mikael A. Kowal*, Marieke Niesters

and Monique van Velzen

PHARMACEUTICAL-GRADE CANNABIS IN CHRONIC PAIN

PATIENTS WITH FIBROMYALGIA: PHARMACOKINETIC EFFECTS

OF THREE CANNABIS VARIETIES

P2-34

Stephanie Lake*, Thomas Kerr, Jane Buxton, Zach Walsh,

Kanna Hayashi, Evan Wood and M-J Milloy

THE ASSOCIATION BETWEEN LOW METHADONE DOSE AND EXTRA-

MEDICAL OPIOID USE IS TEMPERED BY DAILY CANNABIS USE:

PRELIMINARY EVIDENCE OF A BIOLOGICAL INTERACTION

P2-35

Mark A. Lewis* and Kevin Smith

PATIENT FOCUSED INVESTIGATION OF THE ENTOURAGE EFFECT, EXPERIENCE,

AND BENEFITS TO PUBLIC SAFETY AND THE EMERGING

THERAPEUTIC MARKETPLACE

P2-36

Daniel Liput*, Ao Dong, Kaikai He, Henry Puhl, Yulong Li

and David Lovinger

DIRECT MEASUREMENT OF ACTIVITY-DEPENDENT ENDOCANNABINOID

MODULATION IN BRAIN SLICE USING THE NOVEL GENETICALLY-ENCODED

FLUORESCENT SENSOR GRABeCB

P2-37

Margaret PS Luke*, Joanna Borowska, Benjamin J. Smith,

Anna-Maria Szczesniak, Janette Nason, J. Daniel Lafreniere,

Alex Straiker, François Tremblay and Melanie EM Kelly

THE ABSENCE OF MONOGLYCERIDE LIPASE (MAGL) INFLUENCES RETINAL

FUNCTION AFTER PHOTIC INJURY P2-38

Erin Martin*, Nicolas Schlienz, Joel Munson, Heather Jackson,

Marcel Bonn-Miller and Ryan Vandrey

THERAPEUTIC CANNABINOIDS IN ANXIETY AND DEPRESSION:

RESULTS FROM AN OBSERVATIONAL RESEARCH STUDY

P2-39

Rhiannon Mayhugh*, Tory Spindle, Marcel Bonn-Miller

and Ryan Vandrey

PREVALENCE AND IMPACT OF PTSD SYMPTOMS ON SLEEP AND CANNABIS ABSTINENCE IN AN URBAN CANNABIS

TREATMENT TRIAL

P2-40

Leslie McAhren*, Lee Newman and John Adgate

WE DON'T RINSE CANNABIS: EXPOSURE AND HEALTH EFFECTS OF RESIDUAL PESTICIDES IN CANNABIS

P2-41

Meredith Meacham*, Johannes Thrul, Danielle Ramo

and Michael Paul

THC CONTENT AND NUMERIC SUBJECTIVE HIGHNESS REPORTED IN

A REDDIT ONLINE CANNABIS COMMUNITY 2010-2018

P2-42

George Lockwood, Saoirse E. O’Sullivan*, Lisa C.D. Storer

and Richard G. Grundy

IN VITRO EVALUATION OF THE EFFECT OF CANNABIDIOL

AS AN ADJUVANT THERAPY FOR PAEDIATRIC BRAIN TUMOURS

P2-43

Caitlin R. M. Oyagawa*, Braden J. Woodhouse, Michelle Glass

and Natasha L. Grimsey

AGONIST-INDUCED SURFACE UPREGULATION OF CANNABINOID

RECEPTOR 2 (CB2) P2-44

Shelley Paulisin*, Hilary A. Marusak, Allesandra S.

Iadipaolo, Craig Peters and Christine A. Rabinak

EFFECTS OF THE CANNABINOID RECEPTOR 1 GENE ON FEAR

EXTINCTION NEURAL CIRCUITRY IN HEALTHY ADULTS

P2-45

Rimmerman, N*, Gale-Treister, Z, Amiaz, R, Ravona-Springer, R, Weiser M. and Yirmiya, R.

PRELIMINARY RESULTS FROM A STUDY ON THE MOLECULAR

PREDICTORS OF THE EFFICACY OF ELECTROCONVULSIVE THERAPY (ECT)

IN MAJOR DEPRESSION PATIENTS

P2-46

Joseph Rootman*, Michelle St. Pierre, Stacey Squires

and Zachary Walsh

SUBSTITUTING CANNABIS FOR ALCOHOL: THE IMPACT

OF LEGALIZATION P2-47

Craig Workman, John Kindred, Laura Ponto, John Kamholz

and Thorsten Rudroff*

CHRONIC USE OF Δ-9-TETRAHYDROCANNABINOL (THC)

AND CANNABIDIOL (CBD) ON CEREBRAL GLUCOSE METABOLISM IN PEOPLE WITH MULTIPLE SCLEROSIS –

A PILOT STUDY

P2-48

Khan O Saba, Dawn Boothe* and Mansour Mahmoud

ANTICANCER EFFECTS OF CANNABINOID ON HUMAN PROSTATE

CANCER CELL LINE P2-49

Alexandra Sideris*, Crispiana Cozowicz, Jashvant Poeran

and Stavros Memtsoudis

INPATIENT PRESCRIPTION CANNABINOID UTILIZATION RATE IN DIFFERENT SURGICAL COHORTS

IN THE UNITED STATES: A POPULATION-BASED STUDY

P2-50

Rosemary Smith, M. Kathryn Dahlgren, Kelly Sagar, Ashley Lambros*, Madeline Kuppe,

Laura Patriarca and Staci Gruber

BLUNTING THE PAIN: EXPLORING THE IMPACT OF MEDICAL CANNABIS

TREATMENT IN PATIENTS WITH CHRONIC PAIN

P2-51

Jennifer Spohrs*, Martin Ulrich, Laura Bindila, Michael Prost,

Paul Plener, Georg Grön and Birgit Abler

THE ENDOCANNABINOID SYSTEM AS A PREDICTOR OF FEAR EXTINCTION

LEARNING - AN FMRI STUDY P2-52

Stacey Squires*, Sarah Daniels, Joseph Rootman and Zach Walsh

STANDARDIZATION OF CANNABIS DOSE FROM USER-DERIVED RATINGS;

ESTABLISHING THE INDEX OF CANNABIS EQUIVALENCE (ICE)

P2-53

Kevin Takakuwa*, Anthony Mistretta, Vanessa Pazdernik

and Dustin Sulak

THE EDUCATION, KNOWLEDGE, AND PRACTICE CHARACTERISTICS

OF CANNABIS PHYSICIANS: A SURVEY OF THE SOCIETY OF CANNABIS CLINICIANS

P2-54

Nehal P. Vadhan*, Diana Martins-Welch and Jonathan

Morgenstern

DIFFERENCES AND SIMILARITIES IN RECREATIONAL AND MEDICINAL CANNABIS USERS IN THE NY-METRO

AREA: A COMMUNITY SURVEY

P2-55

Denise A. Valenti*, Denning Lam, Kruti BhanuPrasad, Marc Pomplun and Christopher Wu

MARIJUANA/CANNABIS IMPAIRED DRIVING: RETINAL DYSFUNCTION OF RODS, CONES AND GANGLION CELLS

P2-56

Robert Walsh*, Nora Chiang, Philip Kreiter, Katherine Bonson, Silvia Calderon, Michael Klein,

Debra Kelsh, Neta Nelson, Daniel Molina, N. Nora Yang

and Shwe Gyaw

A HUMAN ABUSE POTENTIAL STUDY TO EVALUATE THE SUBJECTIVE

AND PHYSIOLOGICAL EFFECTS OF CANNABIDIOL COMPARED TO

DELTA-9-TETRAHYDROCANNABINOL AND ALPRAZOLAM IN

AN INPATIENT SETTING

P2-57

Daniel Wang*, Harrison Elder, Ryan Lanier, Marilyn Huestis,

Nathaniel Katz and Jack Henningfield

IDENTIFYING AND EVALUATING ABUSE-RELATED EVENTS IN CLINICAL

TRIALS EXAMINING CANNABIS-DERIVED SUBSTANCES

P2-58

Mark Ware*, Maja Kalaba, Chris Murray

and Dominique Audet

PRELIMINARY OVERVIEW OF SELF-REPORTED ADVERSE EVENTS IN MEDICINAL CANNABIS USERS:

RETROSPECTIVE DATABASE ANALYSIS ACCORDING TO PRODUCT POTENCY

COMPOSITION AND FORM

P2-59

Adrianne Wilson-Poe*, Eric Larsen, Conan Liu

and Greis Ari

EFFICACY, SIDE EFFECTS, AND PATTERNS OF MEDICAL

CANNABIS USE AMONG PATIENTS WITH CHRONIC LOW BACK PAIN

P2-60

Nicole L. Zabik*, Allesandra Iadipaolo, Farrah Elrahal, Craig

Peters, Hilary A. Marusak and Christine A. Rabinak

DELTA-9-TETRAHYDROCANNABINOL MODERATES THE EFFECTS OF

AVOIDANCE SYMPTOM SEVERITY DURING FEAR EXTINCTION IN

TRAUMA-EXPOSED INDIVIDUALS

P2-61

Joanna Zeiger*, William Silvers, Ed Fleegler

and Robert Zeiger

CANNABINOID USE IN A POPULATION BASED SURVEY OF ADULT ATHLETES P2-62

Notes: Presenting Author*

POSTER SESSION P3

Wednesday, July 3rd: 16:00 - 18:00

Benedicte Allam-Ndoul*, Frederic Begin, Alain Houde, Nicolas Flamand, Cristoforo Silvestri, Vincenzo Di Marzo

and Alain Veilleux

IMPACT OF THE ENDOCANNABINOIDOME ON SMALL

INTESTINE EPITHELIAL PERMEABILITY P3-1

Shana M. Augustin* and David M. Lovinger

ROLE OF 2-ARACHIDONOYLGLYCEROL IN STRIATAL LONG-TERM DEPRESSION

AND ETHANOL PREFERENCE/ DRINKING BEHAVIOR

P3-2

Courtney A. Bouchet*, Katherine L. Suchland and Susan L. Ingram

ADAPTATIONS IN CANNABINOID RECEPTOR SIGNALING IN THE

VENTROLATERAL PERIAQUEDUCTAL GRAY DURING PERSISTENT

INFLAMMATION

P3-3

James J Burston*, Sam R C Johnson, Victoria J Tyrrell,

Rossa Inglis, Robert Andrews, Jenna Cash, Paul Martin,

Christopher P Thomas and Valerie B O'Donnell

DELETION OF 12/15 LIPOXYGENASE LEADS TO ALTERED REMODELLING

DURING WOUND REPAIR P3-4

Lawrence Carey*, Zhili Xu, Gabriela Rajic, Alexandros

Makriyannis, Julian Romero, Cecilia Hillard, Ken Mackie

and Andrea Hohmann

TARGETING CANNABINOID TYPE 2 RECEPTORS TO SUPPRESS

ANTIRETROVIRAL-INDUCED NEUROPATHIC NOCICEPTION

P3-5

Jakub Chwastek*, Marta Bryk and Katarzyna Starowicz

THE INFLUENCE OF 2-AG ON CHEMOKINES EXPRESSION IN

FIBROBLAST-LIKE SYNOVIOCYTES STIMULATED WITH TNFα

P3-6

Rebecca M. Craft*, Stevie C. Britch, Abby M. Pondelick

and Georgie A. Rosales

NO CANNABINOID RECEPTOR MEDIATION OF ANTINOCICEPTION

PRODUCED BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS

P3-7

Clare Diester*, Matthew Banks and S. Stevens Negus

EFFECTS OF Δ9-THC AND MONOACYLGLYCEROL LIPASE

INHIBITORS ON PAIN-STIMULATED AND PAIN-DEPRESSED ACUTE PAIN

BEHAVIORS IN MICE

P3-8

Narendar Dudhipala*, Corinne Sweeney, Ruchi Thakkar, Tabish

Mehraj, Sushruth Marathe, Waseem Gul, Mahmoud A.

ElSohly, Brian Murphy and Soumyaji Majumdar

INTRAOCULAR PRESSURE LOWERING EFFICACY OF

Δ9-TETRAHYDROCANNABINOL VALINE HEMISUCCINATE LOADED

NANOEMULSION IN A NORMOTENSIVE RABBIT MODEL

P3-9

Matthew Elmes*, Dale Deutsch, Iwao Ojima and Martin Kaczocha

DEVELOPMENT OF ENDOCANNABINOID TRANSPORT INHIBITORS FOR THE

THERAPEUTIC TREATMENT OF PAIN P3-10

Adela García-Martín*, Sonia Burgaz, Carmen Navarrete,

Concepción García, Giovanni Appendino, Alain Rolland,

Javier Fernández-Ruíz and Eduardo Muñoz

COMPARISON OF THE NEUROPROTECTIVE ACTIVITY OF CANNABIGEROL DERIVATIVES IN

HUNTINGTON’S AND PARKINSON’S DISEASE MODELS

P3-11

Sandra Glasmacher* and Jürg Gertsch

BIOCHEMICAL AND ANALYTICAL CHARACTERIZATION

OF PEPTIDE ENDOCANNABINOIDS P3-12

Hannah Y. Gogulski*, Timothy G. Freels, Ryan J. McLaughlin

and Rebecca M. Craft

ANTINOCICEPTIVE EFFICACY OF VAPORIZED CANNABIS

EXTRACTS IN A RAT MODEL OF INFLAMMATORY PAIN

P3-13

Kelsey Guenther*, Cassidy Wideman, Erin Rock,

Cheryl Limebeer and Linda Parker

CONDITIONED GAPING PRODUCED BY DELAYED, BUT NOT IMMEDIATE, EXPOSURE TO COCAINE IN RATS

P3-14

Ozge Gunduz-Cinar*, Sarvar Oreizi-Esfahani, Emma Brockway, Gabrielle Pollack,

Yuhong Lin, Grzegorz Godlewski, Judith Harvey-White,

Resat Cinar, George Kunos and Andrew Holmes

OLEIC ACID SUPPLEMENTATION IN FEAR EXTINCTION P3-15

Shiran Udi, Liad Hinden*, Majdoleen Ahmad, Rivka Hadar,

Malliga R. Iyer, Resat Cinar, Michal Herman-Edelsteinand

and Joseph Tam

OBESITY-INDUCED CHRONIC KIDNEY DISEASE IS AMELIORATED BY DUAL INHIBITION OF CANNABINOID-1

RECEPTOR AND iNOS P3-16

Paula Morales, Dow P. Hurst, Linda M. Console-Bram, Pingwei Zhao, Nadine Jagerovic*, Mary E.

Abood and Patricia H. Reggio

THIENOPYRIMIDINE DERIVATIVES AS GPR55 LIGANDS P3-17

Lindsey Jay*, Olivia Rivellini, Charles Zawatsky, Joshua Park,

Grzegorz Godlewski, Resat Cinar and George Kunos

INVESTIGATING THE STATUS OF THE ENDOCANNABINOID/CB1R SYSTEM

IN CHRONIC ALCOHOL-INDUCED LUNG INFLAMMATION

P3-18

Lipin Ji*, Yingpeng Liu, Anisha Korde, Alex Ciesielski, Alex Straiker, Othman Benchama,

Amey Dhopeshwarkar, Simiao Wu, Chandrashekhar Honrao,

Fei Tong, Ngan Tran, Ken Mackie, Laura Bohn, Alexandros Makriyannis and Spyros Nikas

RETRO ESTER AND AMIDE ENDOCANNABINOID ANALOGUES

WITH RESISTANCE TO ENZYMATIC HYDROLYSIS

P3-19

Clare T Johnson* and Heather B Bradshaw

GPR55 DELETION CAUSES DECREASES IN CNS PROSTAGLANDINS

AND INCREASES IN 2-AG AND RELATED LIPIDS

P3-20

Przemysław Kac*, Jakub Mlost, Marta Bryk and Katarzyna Starowicz

CHRONIC (E)-Β-CARYOPHYLLENE ADMINISTRATION IN RAT MODEL

OF OSTEOARTHRITIS RESULTS IN CB2 AND OPIOID RECEPTOR DEPENDENT

ANALGESIC EFFECT

P3-21

Andrew J. Kesner*, Matthew J. Pava, Karina P. Abrahao and David M. Lovinger

SLEEP DISTURBANCES IN MICE DURING CHRONIC THC

ADMINISTRATION AND ABSTINENCE P3-22

Wook Kim*

PERIPHERAL CANNABINOID 1 RECEPTOR BLOCKADE IMPROVES

INSULIN SENSITIVITY BY SUPPRESSING ADIPOSE TISSUE INFLAMMATION VIA

NLRP3 INFLAMMASOME IN MOUSE MODELS OF OBESITY

P3-23

C. Korn*, A. Osterwald, D. Holzer, E. Zirwes, K. Atz, B. Brennecke, E. M. Carreira, C.

Davies, J. Fingerle, T. Gazzi, J. Gertsch, W. Guba, A. Kimbara, M. Maccarrone, H. Mandhair, R. E. Martin, A. Mason, T. Miljus, M. Nazare, M. Nettekoven, S.

Oddi, P. Pacher, A. Pavlovic, A. Pedrina-McCarthy, P. Pfaff, C. Raposo, M. Rogers-Evans, E. Roome, S. Röver, A. Rufer, R.

Sarott, M. Soethoudt, M. van der Stelt, D. Sykes, Z. Varga, D. B.

Veprintsev, M. Weise, M. Westphal, U. Grether

and C. Ullmer

NOVEL AND HIGHLY SELECTIVE CB2R FLUORESCENT PROBES FOR TRACING CB2R-POSITIVE CELL POPULATIONS

P3-24

Alexis League*, Douglas Hermes, Clare Johnson, Megan Key, Micah Niphakis, Benjamin Cravatt, Ken Mackie, Aron

Lichtman, Bogna Ignatowska-Jankowska and Sylvia Fitting

MONOACYLGLYCEROL LIPASE INHIBITOR MJN110

REDUCES HIV-1 TAT-INDUCED EXCITOTOXICITY IN VITRO

P3-25

Timothy W. Lefever*, Jenny L. Wiley

and Herbert H. Seltzman

THC AND FENTANYL INTERACTION IN RATS: EVALUATION OF

RESPIRATORY EFFECTS AND ADVERSE HEALTH OBSERVATIONS

P3-26

Christian Lehmann*, Ian Burkovskiy and Juan Zhou

INTRAVITAL IMAGING OF INFLAMMATION AND MICROCIRCULATION FOR CANNABINOID RESEARCH

P3-27

Martin Leigh*, Malte Feja, Ajay Baindur, Ken Wakabayashi,

Micah Niphakis, Ben Cravatt and Caroline Bass

ENDOCANNABINOID REGULATION OF CUE-INDUCED INCENTIVE MOTIVATION

IN THE NUCLEUS ACCUMBENS AND VENTRAL TEGMENTAL

AREA OF MALE RATS

P3-28

Fouad Lemtiri-Chlieh, Tiwanna M. Robinson, Jadin L. James

and Eric S. Levine*

BDNF-INDUCED ENDOCANNABINOID RELEASE REGULATES SYNAPTIC

PLASTICITY P3-29

Erika Liktor-Busa*, Beth M. Wiese, Kristen Kallen-

Keck, Krishna Parsawar, Todd W. Vanderah

and Tally Largent-Milnes

ENHANCEMENT OF ENDOCANNABINOID TONE AS A NOVEL TARGET FOR

TREATMENT OF MIGRAINE

P3-30

Ziyi Liu*, Resat Cinar, Tony Jourdan, Grzegorz Godlewski,

Malliga Iyer, Joshua Park, Keming Xiong, Jie Liu

and George Kunos

A DUAL-TARGET PERIPHERALLY RESTRICTED CB1R ANTAGONIST

PROMOTES PERIRENAL FAT BROWNING IN OBESE MICE VIA AMPK SIGNALING

P3-31

Qing-Rong Liu*, Anna Canseco-Alba, Monika Chung, Brandon

Sanabria, Hai-Ying Zhang, Zheng-Xiong Xi, Zhicheng Lin, Hiroki Ishiguro, Paritosh Ghosh

and Emmanuel Onaivi

MICROGLIA AND DOPAMINE NEURON SPECIFIC CNR2 GENE

KNOCKOUT MOUSE BRAINS SHOW CB2R BIASED INFLAMMATION

SIGNALING PATHWAYS

P3-32

Vincent Maida*

TOPICAL MEDICAL CANNABIS-BASED MEDICINES: A NEW EPIGENETIC

PARADIGM FOR INTEGUMENTARY AND WOUND MANAGEMENT

P3-33

Orlaith Mannion*, Emer Power, Hannah Casey, Brendan Harhen,

Michael Scully, Brian E. McGuire and David P. Finn

INVESTIGATION OF THE EFFECTS OF THE PERIPHERALLY RESTRICTED FAAH INHIBITOR URB937 IN A RAT MODEL OF

POST-OPERATIVE PAIN FOLLOWING INGUINAL HERNIA REPAIR SURGERY

P3-34

Jason Middleton*, Elizabeth Fucich, Zachary

Stielper, Heather Cancienne, Scott Edwards, Nicholas Gilpin

and Patricia Molina

NEURONAL PROPERTIES POST TRAUMATIC BRAIN INJURY:

QUANTITATIVE COMPARISON, CLASSIFICATION AND MODULATION

BY CANNABINOID DEGRADATION ENZYME INHIBITORS

P3-35

Tristen Mier*, Amanda Essex, Shawyon Baygani, John Hainline,

Tin Duong, Kylie Black, Alexandria Bell, Ken Mackie

and Anna Kalinovsky

ENDOCANNABINOID MACHINERY REGULATES CEREBELLAR GRANULE

CELL DEVELOPMENT P3-36

Chanté A. Muller*, Diane L. Lynch, Dow P. Hurst

and Patricia H. Reggio

ENDOCANNABINOIDS AND THEIR ACTION AT TRPV1 P3-37

Agnes Tatum-Kuri, Lorena Macías-Triana, Karen Romero-

Cordero, Alba Vera-Barrón, Gloria Arankowsky-Sandoval,

Daniele Piomelli and Eric Murillo-Rodriguez*

CHRONIC INJECTIONS OF WIN 55, 212-2 IN YOUNG RATS CAUSE SLEEP

DISTURBANCES IN ADULTHOOD P3-38

Carmen Navarrete*, Adela García, Martin Garrido, Leyre Mestre, Miriam Mecha,

Ana Feliú, Carmen Guaza, Alain Rolland

and Eduardo Muñoz

EFFECTS OF EHP-101 ON INFLAMMATION AND REMYELINATION

IN MURINE MODELS OF MULTIPLE SCLEROSIS

P3-39

Alexis Papariello*, David Taylor, Ken Soderstrom and Karen Litwa

MAGL REGULATION OF EXCITATORY SYNAPSES IN ASD PATIENT IPSC DERIVED CORTICAL ORGANOIDS

P3-40

Florent Pechereau*, Sébastien Lacroix, Nadine Leblanc,

Alain Houde, Cyril Martin, Nicolas Flamand, Cristoforo Silvestri, Vincenzo Di Marzo

and Alain Veilleux

SMALL INTESTINE METABOLIC AND ENDOCANNABINOIDE ADAPTATION IN

RESPONSE TO AN OBESOGENIC DIET P3-41

Pedro A Perez*, Donovan A Argueta

and Nicholas V DiPatrizio

PERIPHERAL CANNABINOID CB1 RECEPTORS CONTROL NUTRIENT-

INDUCED INCRETIN SECRETION IN VIVO P3-42

Gavin Petrie*, Georgia Balsevich, Tamas Fuzesi, David Rosenegger,

Robert Aukema, Jaideep Bains and Matthew Hill

TONIC ENDOCANNABINOID SIGNALLING GATES STRESS-LIKE

STEREOTYPIC BEHAVIORS P3-43

Samantha L. Pollock*, Sara Rubovits

and Cecilia J. Hillard

THE ROLE OF THE CANNABINOID RECEPTORS IN THE EFFECTS OF

GABAPENTIN ON FORMALIN- INDUCED HYPERALGESIA

P3-44

Julian Romero*, Noelia Aparicio, Diego Herraez, Maria Posada,

Irene Benito-Cuesta, Benjamin Cravatt, Teresa Grande

and Rosa Tolon

FAAH-KO ASTROCYTES EXHIBIT A PRO-INFLAMMATORY PHENOTYPE P3-45

Prabhuanand Selvaraj*, Jie Wen, Mikiei Tanaka, Scott Sackett

and Yumin Zhang

THERAPEUTIC EFFECT OF THE SUBSTRATE-SELECTIVE

CYCLOOXYGENASE-2 INHIBITION IN A MOUSE MODEL OF REPETITIVE

CLOSED HEAD INJURY

P3-46

Zachary Stielper*, Elizabeth Fucich, Garrett Sauber, Cecilia Hillard, Scott Edwards,

Patricia Molina and Nicholas Gilpin

TRAUMATIC BRAIN INJURY ALTERS THE ENDOCANNABINOID SYSTEM

IN THE BASOLATERAL AMYGDALA OF FEMALE RATS

P3-47

Richard A. Slivicki* and Robert W. Gereau IV

IMPACT OF A PERIPHERALLY RESTRICTED CANNABINOID AGONIST

ON INFLAMMATION-INDUCED NOCICEPTION AND TRPV1

SENSITIZATION IN DORSAL ROOT GANGLION NEURONS

P3-48

John Starkus, Chad Jansen, Lori Shimoda, Alexander Stokes,

Andrea Small-Howard* and Helen Turner

POTENTIAL DEVELOPMENT OF NOVEL ANALGESICS THROUGH ACTIONS OF MINOR CANNABINOIDS TARGETING

TRANSIENT RECEPTOR (TRP) SUPERFAMILY MEMBERS TRPV1,

TRPV2, TRPM8 AND TRPA1

P3-49

John Starkus, Chad Jansen, Lori Shimoda, Mark Speck,

Alexander J Stokes, Joel Kawakami,

Andrea Small-Howard* and Helen Turner

TERPENE REGULATION OF TRPV1: POTENTIAL PAIN THERAPEUTICS P3-50

Noori Sotudeh*, Paula Morales, Dow Hurst, Diane Lynch

and Patricia Reggio

MECHANISM OF ACTIVATION OF GPR18 BY ITSELF P3-51

Floyd F. Steele*, Sara R. Nass and Steven G. Kinsey

ANTI-ARTHRITIC EFFECTS OF ENDOCANNABINOID ENZYME

INHIBITION IN A MOUSE MODEL OF INFLAMMATORY ARTHRITIS

P3-52

Gergő Szanda*, Éva Wisniewski and Viktória Horváth

EXPRESSION LEVEL INDEPENDENT INHIBITION OF LEPTIN RECEPTOR

EXPRESSION BY THE CANNABINOID TYPE-1 RECEPTOR (CB1R)

P3-53

Mikiei Tanaka*, Kazuya Yagyu, Scott Sachett and Yumin Zhang

ANTI-INFLAMMATORY EFFECTS BY PHARMACOLOGICAL INHIBITION

OR KNOCKDOWN OF FATTY ACID AMIDE HYDROLASE IN BV2

MICROGLIAL CELLS

P3-54

Louise Topping*, Felix Clanchy, Fiona McCann, Ruth Gallily, Marc Feldmann,

Raphael Mechoulam and Richard Williams

ANALYSIS OF THE ANTI-INFLAMMATORY AND

ANALGESIC EFFECTS OF CANNABIDIOL IN ARTHRITIS

P3-55

Yudisleydis Valdés*, Hery Chung, Jaime Mella-Raipán,

Mario Faúndez and Carlos David Pessoa-Mahana

DEVELOPMENT OF BENZOIMIDAZOLIC STRUCTURE INHIBITORS OF HUMAN

FATTY ACID AMIDE HYDROLASE ENZYME (h-FAAH)

P3-56

Dana Vaughn*, Justyna Kulpa, Lina Paulionis, Bill Milgram

and Gary Landsberg

THE CORRELATION OF ANANDAMIDE AND CORTISOL IN DOGS FOLLOWING

AN ACUTE STRESSOR P3-57

Haley A. Vecchiarelli*, Vincent Chiang, Kaitlyn Tan, Min Qiao, Catherine M. Keenan, Samantha

L. Baglot, Robert J. Aukema, Gavin N. Petrie, Quentin J. Pittman, Keith A. Sharkey

and Matthew N. Hill

INVESTIGATING THE RELATIONSHIP BETWEEN INFLAMMATION AND

ENDOCANNABINOIDS IN THE AMYGDALA DURING COLITIS

P3-58

MariaLuisa Vigano*, Rihab Gamaoun, Popi Kasvis

and Antonio Vigano

CANNABIS AS A COMPLEMENTARY PALLIATIVE CARE TREATMENT FOR CANCER PATIENTS: EXPLORATORY

ANALYSIS OF DATA FROM THE CANNABIS PILOT PROJECT OF THE

MCGILL UNIVERSITY HEALTH CENTRE

P3-59

Rihab Gamaoun, Popi Kasvis, Maria-Fernanda Arboleda,

Gligorka Raskovic, Filareti Patronidis

and Antonio Vigano*

POTENTIAL IMPACT OF MEDICAL CANNABIS TREATMENT ON PAIN

CONTROL AMONG CANCER PATIENTS IN QUEBEC – CANADA: THE CANNABIS

PILOT PROJECT AT THE MCGILL UNIVERSITY HEALTH CENTRE

P3-60

Popi Kasvis, MariaLuisa Vigano and Antonio Vigano*

THE EFFECT OF MEDICAL CANNABIS ON APPETITE IN CANCER ANOREXIA: POTENTIAL MECHANISM OF ACTION

AND PRELIMINARY RESULTS

P3-61

Brynna Webb*, Kylie Black, John Hainline,

Athanasios Liodos, Jacob LaMar, Ricardo Martinez,

Tin Duong, Ken Mackie and Anna Kalinovsky

ENDOCANNABINOID SIGNALING AFFECTS PINCEAU STRUCTURE P3-62

Brynna Webb*, Kylie Black, John Hainline, Athanasios Liodos,

Jacob LaMar, Alexandria Bell, Ken Mackie

and Anna Kalinovsky

ENDOCANNABINOID SIGNALING REGULATES CEREBELLAR BEHAVIORS P3-63

Beth M. Wiese*, Erika Liktor-Busa, Alexandros Makriyannis,

Tally M. Largent-Milnes and Todd W. Vanderah

THE ROLE OF CANNABINOID RECEPTOR MEDIATION OF OPIOID INDUCED

RESPIRATORY DEPRESSION IN THE PREBÖTZINGER COMPLEX

P3-64

Charles Zawatsky*, Joshua Park, Nathan Coffey, Lindsey Jay,

Grzegorz Godlewski, George Kunos

and Resat Cinar

THE ROLE OF CANNABINOID RECEPTOR 1 (CB1R) IN ALVEOLAR TYPE-2 EPITHELIAL AND MYELOID

CELLS IN EXPERIMENTAL LUNG FIBROSIS DEVELOPMENT

P3-65

Schuyler Pruyn, Andrew Thurston

and HaiAn Zheng*

BIODISTRIBUTIONS AND FUNCTIONS OF ENDOCANNABINOIDS

ACROSS THE BLOOD BRAIN BARRIER UNDER NORMAL

AND ISCHEMIC CONDITIONS

P3-66

Notes: Presenting Author*

Plenary Speaker

Sunday, June 30, 2019 11:30 – 12:30

US CANNABIS POLICY:

IMPLICATIONS FOR PUBLIC HEALTH

Susan R. B. Weiss, Ph.D.

Director Division of Extramural Research

National Institute on Drug Abuse, Bethesda, MD, USA

Across the United States and the world, cannabis policies are changing rapidly, with public health impacts that cannot yet be foreseen based on the current state of our knowledge. Over the past decade, cannabis use has increased in young and older adults, and each year at least 4 million people in the U.S. meet diagnostic criteria for cannabis use disorder. The non-alignment of Federal and State laws creates obstacles for researchers, public health officials, and patients, as well as those in the cannabis industry. So does the fact that cannabis products vary widely in potency (i.e., tetrahydrocannabinol (THC) concentrations), constituents, and formulations. Edibles and concentrated THC products may pose particular health and safety risks; cannabidiol (CBD) products are now widely available to treat myriad conditions with little or no regulation.

This presentation will highlight the emerging public health and safety data from U.S. states that have implemented medical or adult use marijuana laws, with a focus on the challenges of implementing policies to minimize harm. It will also summarize what we currently know and what we still need to know about the adverse effects of cannabis and cannabinoids, as well as their potential therapeutic effects, so that we can better identify research needs and opportunities. More research on the long-term impact of cannabis use, particularly in adolescents, pregnant women (and their offspring), and persons with mental illness is greatly needed, as these groups are potentially the most at risk for adverse outcomes. Also, despite the widespread use of “medical marijuana” and CBD products, the potential therapeutic uses of cannabis and its constituent compounds require a great deal more study. To do so will require continuing to address long-standing barriers to research. As data accumulate, it will be important to remain unbiased in the assessment of both cannabis’s harms and its benefits, so that the advancing science can most effectively inform policy and benefit the public health.

ICRS Lifetime Achievement Award

Sunday, June 30, 2019 13:30 – 14:30

CANNABINOID PHARMACOLOGY: MY FIRST HALF CENTURY

Roger Pertwee MA, DPhil, DSc, HonFBPhS

Institute of Medical Sciences University of Aberdeen, Aberdeen, Scotland, UK

My cannabinoid research began at Oxford University, England, in the late 1960s, not long after the structural elucidation and first synthesis by Raphael Mechoulam et al. of two notable phytocannabinoids: Δ9-tetrahydrocannabinol (THC) and cannabidiol.

The 1970s, 80s and 90s. In some of my initial research, I (1) contributed to the discovery in cannabis of the phytocannabinoid, tetrahydrocannabivarin, and to its initial pharmacological characterization, (2) developed the mouse ring test, an in vivo assay for measuring catalepsy induced, for example, by THC, and (3) discovered that THC lowers the thermoregulatory set point in mice, such that they still regulate their core temperatures, but at “sub-normal” levels.

After moving to Aberdeen University in 1974, I continued my cannabinoid research, for example by developing an “ex vivo” assay for “THC-like” drugs. This is performed with murine isolated vasa deferentia in which CB1 agonists can produce concentration-related reductions in the size of electrically-evoked smooth muscle contractions, reductions now known to result from CB1 receptor-mediated inhibition of the neuronal release of contractile transmitters. I used this assay in a project led by Raphael Mechoulam that began in the late 1980s, and was prompted by the then recent discovery of CB1 receptors. This project provided the first evidence (1) that the endogenous compound, anandamide, is a CB1 agonist and so an “endocannabinoid” and hence (2) for the existence of an “endocannabinoid system” of cannabinoid receptors and “endocannabinoids”.

In the early 1990s I also helped found the ICRS, and later in that decade, interacted with the UK Government, with Medical organizations, and with UK and US multiple sclerosis patients who were self-medicating with cannabis. This I did in a manner that helped to encourage new medicalization of cannabis-derived cannabinoids.

The 21st century In this century, research in my laboratory has, for example, contributed to the discovery and/or development of (1) a water soluble synthetic analogue of THC, O-1057, (2) an allosteric site on the CB1 receptor, and (3) novel synthetic compounds that behave as positive allosteric modulators (PAMs) of CB1 or CB2 receptors. These PAMs include two CB1 PAMs (GAT211 and GAT229) that collaborators have shown to possess therapeutic potential for relieving neuropathic pain or ocular glaucoma, and a CB2 PAM (EC-21a) that may, for example, have therapeutic potential for the treatment of blood cancer. My laboratory also recently helped to identify novel actions of the phytocannabinoids, cannabidiol, cannabidiolic acid, cannabigerol and tetrahydrocannabivarin, and of a stable synthetic analogue of cannabidiolic acid. These novel actions have revealed important potential therapeutic uses for most of these compounds.

In the more distant past, my laboratory also contributed to the pharmacological characterization of certain notable synthetic cannabinoids, including methanandamide, ACEA, ACPA, AM251, AM281, AM630 and HU-308, that had been designed and synthesized in the laboratories of some fantastic collaborators. Indeed, throughout the last half century, my research has involved productive and “synergistic” collaborations with many great scientists, based, for example, in Israel, the UK, the USA, Canada, Australia, Italy, Spain, Germany, Poland, Mexico or Russia.

Plenary Speaker

Monday, July 1, 2019 11:30 – 12:30

THE NEUROBIOLOGY OF DRUG

ADDICTION: FROM DRUG REWARD TO HYPERKATIFEIA TO NEGATIVE

REINFORCEMENT

George Koob, Ph.D.

Director

National Institute on Alcohol Abuse and Alcoholism Rockville, MD, USA

Addiction is a chronically relapsing disorder characterized by compulsive drug seeking that is hypothesized to derive from multiple sources of motivational dysregulation. Positive reinforcement, incentive salience and pathological habits derive from super activation of reward neurotransmitter systems in the basal ganglia and set up negative reinforcement during withdrawal. The construct of negative reinforcement, defined as drug taking that alleviates a negative emotional state (hypohedonia, dysphoria, anxiety, hyperalgesia, irritability, and sleep disturbances- all comprising the term “hyperkatifeia”), is an addition source of motivation for compulsive drug seeking in addiction. The hyper negative emotional state associated with addiction has been termed hyperkatifeia from the Greek “katifeia” for “dejection or sadness” and is created by abstinence in the withdrawal/negative affect and protracted abstinence in the preoccupation/anticipation stages of the addiction cycle. In animal models, repeated extended access to drugs of abuse results in negative emotion-like states reflected in increased reward thresholds, decreased pain thresholds, anxiety-like and dysphoric-like responses. Such negative emotional states that drive negative reinforcement are hypothesized to derive not only from “within system” dysregulation of key neurochemical circuits that mediate incentive-salience/reward systems (dopamine, opioid peptides) in the ventral striatum but also from the” between system” recruitment of brain stress systems (corticotropin-releasing factor, dynorphin, norepinephrine, hypocretin, vasopressin, glucocorticoids and neuroimmune factors) in the extended amygdala. Excessive drug taking is also accompanied by deficits in executive function produced by neurocircuitry dysfunction in the medial prefrontal cortex that may facilitate the transition to compulsive-like responding and relapse. Thus, compelling evidence exists to argue that plasticity in the brain pain emotional systems is triggered by acute excessive drug intake, is sensitized during the development of compulsive drug taking with repeated withdrawal, persists into protracted abstinence, and contributes to the development and persistence of compulsive drug seeking.

Young Investigator Award Presentation

Monday, July 1, 2019 13:30 – 14:00

ANANDAMIDE, FAAH, STRESS AND ANXIETY:

A TRANSLATIONAL JOURNEY

Matt Hill, Ph.D.

Associate Professor The Hotchkiss Brain Institute

University of Calgary, Alberta, Canada

Endocannabinoid signalling has been well characterized as a modulator of the stress response, but divergent roles of anandamide (AEA) and 2-arachidonoylglycerol (2-AG) have been identified. Work from our lab, and others, has found that in rodent models stress results in a rapid induction of FAAH activity, which results in an attenuation of apparent "tonic" signaling at the CB1 receptor. This loss of AEA signaling, particularly within the amygdala, appears to contribute to the generation of a stress response as inhibition of FAAH can reverse a multitude of neurobehavioral and endocrine responses to stress. The relevance of FAAH and AEA signaling in humans has also been examined by characterizing the impact of a gene variant in the FAAH gene (C385A) which results in a protein destabilization of FAAH and an elevation of AEA signaling. Consistent with the rodent data, carriers of the C385A allele of the FAAH gene exhibit reduced anxiety and fear, dampened responses to stress and blunted activation of the amygdala in response to threatening stimuli. More recently, we have begun to explore the impacts of pharmacological FAAH inhibition in humans to determine its impact on measures of fear and stress responsively as well. Together, these data provide a strong translational platform to indicate that AEA signaling may gate activation of the amygdala in response to stress and thus limit the generation of emotional states, such as fear and anxiety, and thus targeting FAAH may be a novel pharmacological approach to treating stress-related psychiatric disorders in humans.

Kang Tsou Memorial Speaker

Tuesday, July 2, 2019 12:00 – 13:00

VEGAS AND ULTRA-LSD: NEW CHEMICAL

AND SYNTHETIC BIOLOGICAL TECHNOLOGIES

Bryan Roth, M.D., Ph.D.

Director NIMH Psychoactive Drug Screening Program

Distinguished Professor, Department of Pharmacology UNC Chapel Hill, NC, USA

In this talk I will highlight two new technologies. VEGAS is a synthetic biology technology which provides a platform for the directed evolution of proteins towards defined molecular objectives. I will show how this technology enables the creation of synthetic transcription factors, engineered receptors and allosteric state-dependent nanobodies. Ultra-LSD is an approach which provides a platform for the discovery of novel chemical matter from ultra-large virtual chemical libraries (Lyu, Wang et al, Nature 2019 for example). Recent examples will be provided which illustrate the potential utilities and power of these approaches.

President’s Lecture

Wednesday, July 3, 2019 15:00 – 16:00

The Structures and Functions of the Cannabinoid Receptors

Alexandros Makriyannis, Ph.D.

George D. Behrakis Chair of Pharmaceutical Biotechnology Director, Center for Drug Discovery (CDD) Northeastern University, Boston, MA, USA

Although a number of cannabinoid analogs had been synthesized beginning in the 1960’s, the discovery of the first cannabinoid receptor (CB1) took several decades. This happened through the joint efforts of a number of laboratories, and it involved the use of photoaffinity labelling of radioligands and imaging. The need for obtaining structural information on both CB1 and CB2 to serve as templates in target-based discovery led to computational efforts based on mutational studies for receptor modeling. More extended structural work involving the use of covalent ligands, targeted mutations and proteomic approaches in our laboratory, under the designation of Ligand Assisted Protein Structure (LAPS), provided more detailed experimental data and identified helix 6 in both receptors as being a key site involved in their activation/deactivation, validating some of the earlier computational efforts. An intensive effort involving Scripps, iHuman in Shanghai, and our laboratory, the Center for Drug Discovery led to the crystal structure of the CB1 receptor, first in its inactive form using a suitably designed antagonist for crystallization and subsequently in its activated form, using two irreversible agonists. This work provided detailed information on the binding motif of CB1 ligands. It also validated the concept of a double-toggle (HX6 – Hx3) mechanism of activation. These first two successes were followed by the very recent crystallization of the CB2 receptor, which provided some initial evidence for the complementarity of the two receptors and introduced the activation/deactivation (ying-yang) receptor concept, which now serves as a basis for the development of CB2 agonist/CB1 antagonist therapeutic medications. The availability of detailed structural information of a number of CB1 and CB2 ligand complexes, coupled with data on ligand-receptor dynamics, opens the door for the design of cannabinergic drugs with greater structural and functional specificity. The work also allows us, retrospectively, to examine the functional basis and potential improvement of pharmacologically useful ligands of potential therapeutic value. These include neutral antagonists, megagonists, functionally selective ligands, and CB1 irreversible chemical knock-out antagonists.

Copyright © 2019 International Cannabinoid Research Society